

CURRICULUM VITAE

Name: Barry J. Goldstein, M.D., Ph.D., F.A.C.E.

Academic Office: Room 349 Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107

Clinical Office: Suite 600, Walnut Towers, 211 S. 9th Street, Philadelphia, PA 19107

Phone: (215) 503-1272

Fax: (215) 923-7932

Medical License MD-046797L (PA)

E-mail: Barry.Goldstein@jefferson.edu

Current Position: Director, Division of Endocrinology, Diabetes and Metabolic Diseases,
Department of Medicine, Jefferson Medical College, Philadelphia, PA
Professor of Medicine and Biochemistry and Molecular Pharmacology,
Thomas Jefferson University, Philadelphia, PA

Education:

1976 B.S. (with Distinction) Cornell University, Ithaca, NY

1982 M.D. (with Honor) University of Rochester School of Medicine, Rochester, NY

1982 Ph.D. (Biochemistry) University of Rochester School of Medicine

Postdoctoral Training:

Internship and Residencies:

1982-83 Intern in Medicine, Strong Memorial Hospital, Rochester, NY

1983-85 Associate Resident in Medicine, Strong Memorial Hospital

Fellowships:

1986-88 Research Fellow in Medicine, Harvard Medical School, Boston, MA

1986-88 Research Fellow, Section on Cellular and Molecular Physiology, Elliott P. Joslin
Research Laboratory, Joslin Diabetes Center, Boston, MA

1986-89 Research/Clinical Fellow, Divisions of Endocrinology, Diabetes and Metabolism,
Department of Medicine, Brigham and Women's Hospital, Boston, MA

Licensure and Certification:

1983 New York State License Registration

1986 Massachusetts License Registration

1983 Diplomate, National Board of Medical Examiners

1985 Certified, American Board of Internal Medicine

1989 Certified, Subspecialty Board of Endocrinology, Diabetes and Metabolism

1992 Pennsylvania License Registration

Academic Appointments:

1985-86 Clinical Instructor in Medicine, University of Rochester

1988-90 Instructor in Medicine, Harvard Medical School

1990-92 Assistant Professor of Medicine, Harvard Medical School

1992- Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson
Medical College, Thomas Jefferson University (TJU), Philadelphia, PA

1992-97 Associate Professor of Medicine, TJU

1992- Associate Professor of Biochemistry and Molecular Pharmacology, TJU

1997- Professor of Medicine, TJU

1997- Professor of Biochemistry and Molecular Pharmacology, TJU

2006- Professor of Medicine (with Academic Tenure), TJU

Hospital Appointments:

1985-86 Associate Attending Physician, Highland Hospital, Rochester, NY
1989-92 Associate Physician, Brigham and Women's Hospital, Boston, MA
1992- Active Attending Staff, Thomas Jefferson University Hospital, Philadelphia, PA
1993- Active Medical Staff, Wills Eye Hospital, Philadelphia, PA
1997- Active Medical Staff, Methodist Hospital, Philadelphia, PA

Other Professional Positions and Major Visiting Appointments:

1988-92 Investigator, Section on Cellular and Molecular Physiology, Elliott P. Joslin
Research Laboratory, Joslin Diabetes Center, Boston, MA
1994-96 Affiliate Medical Staff, Joslin Diabetes Center, Boston, MA

Awards and Honors:

1975 Phi Kappa Phi Undergraduate Honor Society
1976 B.S. with Distinction, Cornell University, Ithaca, New York
1976-82 NIH Medical Scientist (M.D./Ph.D.) Program Fellowship
1977 Student Fellowship, Rochester Regional Diabetes Association
1980 Rochester Regional Diabetes Association, Research Award
1981 Alpha Omega Alpha Honor Medical Society
1982 M.D. with Honor, University of Rochester School of Medicine
1982 Doran Stephens Award, University of Rochester School of Medicine
1986-89 Pfizer Postdoctoral Fellowship Award (Diabetes)
1988 Diamond Award and Key Contribution Award, Harvard Community Health Plan
1989-91 The Medical Foundation of Boston, Research Award
1990-91 American Diabetes Association, Research and Development Award
1994 Session Chair, Insulin Action, 15th IDF Congress, Kobe, Japan
1995 Outstanding Investigator Award, Dept. of Medicine, Jefferson Medical College
1995 John R. Williams Lectureship, Highland Hospital, University of Rochester
1996 Elected to the American Society for Clinical Investigation
1996 Edward Rose Lectureship, Philadelphia Endocrine Society
1997 Elected to Fellowship, American College of Endocrinology
1998 Frank A. Bove Memorial Lectureship, Methodist Hospital, Thomas Jefferson University
1998 Elected to the Interurban Clinical Club
2006 Elected to the Association of American Physicians (AAP)

Editorial and Review Activities:

Associate Editor:

2000-2005 Journal of Clinical Endocrinology and Metabolism
2001-2006 DIABETES
2007- Clinical and Translational Science

Editorial Boards:

1995-2000 American Journal of Physiology (Endocrinology and Metabolism)
2000- Endocrine, Metabolic & Immune Disorders - Drug Targets
2001-2003 CME Newsletter, InforMed on Diabetes
2002-2004 CME Newsletter, Dialogues in Diabetes
2005- CMEonDiabetes, web-based CME curriculum (www.CMEonDiabetes.com)
2006- International Journal of Clinical Practice
2007- The Open Endocrinology Journal
2007- Clinical Medicine: Endocrinology and Diabetes (Open access)

Curriculum Development

- 1996 Conference syllabus consultant, Outcomes & Disease Management of Diabetes
- 1999-2003 INCE Teleconferences on Diabetes Mellitus conducted nationwide
- 1999-2001 COMED Teleconferences on Diabetes Management conducted nationwide
- 1999- Section Editor, Endocrinology and Diabetes, eMedicine on-line textbook
- 1999 Advisory Board for Special Report on Insulin Resistance, American Pharmaceutical Assoc
- 2004 Advisory Board for Endocrine Society Monograph: "Handbook on Obesity in America"

Manuscript Reviews:

- 1989- Endocrinology, Journal of Clinical Endocrinology and Metabolism, Diabetologia
- 1990- Diabetes, Journal of Clinical Investigation, Journal of Biological Chemistry, Journal of Receptor Research, Molecular Endocrinology, Metabolism
- 1991- Biochemistry, American Journal of Physiology, Diabetes Care
- 1992- European Journal of Biochemistry, American Journal of Medicine
- 1994- Life Sciences, Steroids, Molecular and Cellular Biology
- 2004- Antioxidants and Redox Signaling
- 2005- Cell Metabolism, Nature Clinical Practice Endocrinology & Metabolism

Abstract Reviews:

- 1995 American Diabetes Association Annual Meeting Scientific Sessions
- 1996 International Congress of Endocrinology Scientific Sessions

Certification Examinations:

- American Board of Internal Medicine
- 1992-1995 Physician Secretary, Self-Evaluation (Recertification) Program Subcommittee for Endocrinology, Diabetes and Metabolism
- 1996-2002 Physician Secretary, Subspecialty Board on Endocrinology, Diabetes and Metabolism

Grant Proposals:

- 1990- Veteran's Administration Medical Research Service
- 1991- National Science Foundation

National Institutes of Health

- 1993 Member, Special Review Committee DK-93-10, "Human Genes for NIDDM"
- 1993 Special Reviewer, Metabolism Study Section
- 1994- NIH Reviewer's Reserve
- 1995-99 Regular Member, Metabolism Study Section
- 2000-04 Ad Hoc Reviewer, Metabolism Study Section
- 2001-04 Ad Hoc Reviewer, Endocrinology Study Section
- 2004 NIH Special Emphasis Review Panel for NIH Roadmap Initiative RFA
- 2005- Ad Hoc Reviewer, Cellular Aspects of Diabetes and Obesity (CADO) Study Section
- 2005- Program project study section for Diabetes and Metabolism
- 2006- Reviewer, Special Emphasis Panels, CADO Study Section

American Diabetes Association

- 2005- Member, Research Grant Review Committee

Corporate Consulting and Advisory Board Activities:

1998-00 HMR Oaktree Health Plan Pharmacy and Therapeutics Committee
1997-2005 Scientific Advisory Board, Animas Corporation
1998- Diabetes Advisory Board, GlaxoSmithKline
1999-2000 EMEA Steering Committee on Metabolic Consequences of HIV/HAART
1999-2001 Algorithm Review Faculty, Institute for Healthcare Quality, Inc.
2000 Scientific Advisory Board, Wyeth-Ayerst Research
2000- Diabetes Advisory Board, AstraZeneca Pharmaceuticals
2001 Scientific Advisory Board, DelRx Corporation (insulin delivery devices)
2002 Consultant: Tularik; Medinox; Lilly ICOS
2003- Scientific Advisory Board, BristolMyers Squibb; KOWA corporation
2004- Consultant, Warburg Pincus
2005- Consultant, ONO Corporation; Barr Pharmaceuticals
2005- Member, Clinical Trial Outcomes Adjudication Committee, GlaxoSmithKline
2006- Scientific Advisory Board, Ortho Clinical Diagnostics
2007- Scientific Advisory Board, Omentec Pharmaceuticals
2007- Data Safety Monitoring Board, Wyeth Research Clinical Trials
2007- Endpoint Adjudication Committee, GlaxoSmithKline APPROACH study
2007- Consultant, MetaBasis Therapeutics, Dainippon Sumitomo Pharma

Membership and Activities in Professional Societies:

1984- American Diabetes Association
Philadelphia Chapter
1993-2000 Member, Board of Directors
1996-1998 Vice-President
1998-2000 President
1993- Professional Education Committee (Chair 1996-98)
1995-98 Chair, Local Researcher's Day
1997-98 Chair, Annual Scientific and Clinical Symposium
Greater Philadelphia and Southern New Jersey Region
2006- Member, Leadership Council Board of Directors
National Organization
2005- Member, Research Grant Review Committee
1986- American College of Physicians
2004- Speaker, Endocrinology Review Section, IM Board Recert Course
1988- American Association for the Advancement of Science
1988- American Federation for Clinical Research
1990- The Endocrine Society
National Organization
2003-2006 Member, Public Relations / Media Advisory Committee
2004- Obesity Advisory Committee
1991- American Society for Biochemistry and Molecular Biology
1992- Philadelphia Endocrine Society
1993-98 Member, Board of Directors
1994-95 Secretary/Treasurer
1995-96 Vice President
1996-97 President
1992- Association of Program Directors for Endocrinology and Metabolism

2002-2005 Member, Administrative Council
 1992- American Association of Clinical Endocrinologists
 1997-1999 Member, Endocrine Training Liaison Committee
 1992-2003 American Board of Internal Medicine
 1993- Pennsylvania Interurban Nutrition Club
 1994- Association of Subspecialty Professors
 1996- American Society for Clinical Investigation (ASCI)
 1998 Interurban Clinical Club (Osler Society)
 2004-2006 Councilor for Philadelphia
 2006 Association of American Physicians (AAP)

Multicenter NIH Clinical Trials Activities

NIH: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
 2004- Member, External Hypoglycemia Monitoring Committee
 NIH: Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS)
 1996- Member, Outcomes Classification / CVD and Glucose Adjudication Committee

Basic Research Grants:

1976-82 NIH Medical Scientist (M.D./Ph.D.) Training Program Fellowship
 1977 Student Fellowship Grant-in-Aid, Rochester Diabetes Association
 1986-89 Pfizer Postdoctoral Fellowship Grant (Diabetes)
 1989-91 The Medical Foundation of Boston, Postdoctoral Research Grant Award
 1989-91 NIH DK36836, Diabetes/Endocrinology Research Center, PI, Pilot and Feasibility Study:
 “Cloning of the Rat Liver Insulin Receptor cDNA”
 1990-92 NIH R01 DK31036, Co-Investigator, “Insulin Receptor Structure and Turnover”
 1990-91 American Diabetes Association, Research and Development Award, “Molecular Cloning of
 Hepatic Protein-Tyrosine Phosphatases”
 1991-95 NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action”
 1996-97 NIH R01 DK45592, PI, “Insulin Action in Liver from NIDDM and Obese Humans”
 1992-95 Wyeth-Ayerst Research, PI, “Large-Scale Expression and Purification of PTPases”
 1994-96 National Institutes of Health, Co-Inv., Type 1 Diabetes Prevention Trial
 1994-2002 NIH U01 DK48468, Co-PI, Diabetes Prevention Program (DPP)
 2001- Principal Investigator
 1996-00 NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” (Renewal)
 1995-97 Juvenile Diabetes Found., PI, “Insulin Action in PTPase Knock-out Mice”
 1995 Bayer Pharmaceuticals, PI, “Development of Lines of PTPase Knock-out Mice”
 1996 Hoffman-LaRoche, PI, “PTPase Expression in Insulin-Resistant States.”
 1997 Animas Corporation, PI, “FTIR Spectroscopic Investigation of Blood from Patients for the
 Accurate Measurement of Blood Glucose.”
 1997-98 Tolz Fund Grant (Weizmann Institute/Jefferson), Co-Inv., “Regulation of Insulin Receptor
 Trafficking by its Downstream Effectors: Role of Annexin II and IRS-1.”
 1998-02 NIH R01 DK53388, PI, “Tyrosine Phosphatases in Human Obesity and Diabetes”
 1999-03 American Diabetes Association, Mentor-Based Post-Doctoral Fellowship Grant
 2001-05 NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” (Renewal)
 2002- NIH U01 DK48468, PI, Diabetes Prevention Program Outcomes Study (DPPOS)
 2003-05 Amer Diab Assoc, PI, “Adiponectin: Effects on Endothelial Function and Insulin Signaling”
 2004-05 Thomas Jefferson Pilot Grant Program, “Insulin Signaling and Diabetic Nephropathy
 in Transgenic Models Lacking Expression of the NAD(P)H Oxidase Homolog Nox4.”
 2004-08 NIH RO1 DK063018 PI, "Adiponectin: Vascular Responses and Signaling Mechanisms"
 2004-08 NIH RO1 DK071360 PI, “Adiponectin Improves Vascular Function In High Glucose”

- 2005-08 GlaxoSmithKline, PI, Investigator-Initiated Basic research project, "Are the Effects of Rosiglitazone on Endothelial Function in Insulin Resistance Mediated by Adiponectin?"
- 2005-10 NIH R01 DK43396, PI, "Protein-Tyrosine Phosphatases in Insulin Action" (Renewal)
- 2005-08 PA Dept. Public Health (C.U.R.E.) Program, Co-Inv, Ma (PI), "Adiponectin: Cardioprotective effects and signaling mechanisms"
- 2005-08 American Diabetes Association, Co-Inv, Ma (PI), "Reactive Nitrogen Species and Cardioprotection of Adiponectin"
- 2006-07 Dept. of the Army 03163015, Co-Inv, Joseph (PI), "Artificial Pancreas for Control of Blood Glucose in Hospitalized Patients with Diabetes and Stress Hyperglycemia"
- 2006-10 PA Dept. Public Health , Co Inv, Falkner (PI) Center of Excellence on Research in Obesity
- 2006-11 NIH U01 DK076133, Co-Inv, Sharma (PI), "Adiponectin and Nox4 in Diabetic Kidney Disease"

Clinical Research Grants:

- 1993-4 Lilly, PI, LY275585 vs. Humulin R: Premeal therapy in new type 2 patients.
- 1993 Lilly, Co-Inv., LY275585 vs. Humulin R: Premeal therapy in type 2 diabetes patients.
- 1993-95 Miles, Co-Inv., Miglitol (BAY m1099) in African-American NIDDM patients.
- 1993-94 Pratt Pharmaceuticals, Co-investigator, Glipizide GITS efficacy and safety trial.
- 1994-95 Lilly, PI, Long term monitoring of safety in patients treated with LY275585.
- 1994-96 Alteon/Marion Merrell Dow, PI, Aminoguanidine in diabetic nephropathy.
- 1994-95 Novo-Nordisk, PI, Comparison of BID 70/30 prefilled with QD Novolin-N
- 1994-95 Amylin, PI, Tri-pro-amylin in subjects with type 1 diabetes.
- 1994-97 Sanofi, PI, Intermittent cyclical tiludronate in post-menopausal osteoporosis.
- 1995 Parke-Davis, PI, Placebo-controlled study of troglitazone in type 2 diabetes.
- 1995 SmithKline Beecham, PI, BRL49653C (rosiglitazone) in type 2 diabetes.
- 1995 Alteon, Co-PI, Aminoguanidine in diabetic patients with ESRD on dialysis.
- 1996 Genentech, Inc., PI, Recombinant hIGF-1 with insulin in type 2 diabetes mellitus.
- 1996 Novo-Nordisk, Inc., PI, Repaglinide in type 2 diabetes: maintenance study.
- 1996 SmithKline Beecham, PI, BRL 49653C therapy in patients with NIDDM.
- 1996 Parke-Davis, Co-Inv., CI-991 on treatment targets in insulin-taking NIDDM diabetes patients.
- 1997 SmithKline Beecham, PI, Safety and efficacy of BRL 49653C as monotherapy.
- 1997-98 SmithKline Beecham, PI, BRL49653C added to glyburide in type 2 diabetes.
- 1997-98 Hoechst Marion Roussel, PI, HOE 901 vs. NPH human insulin in type 1 diabetes.
- 1998 Futrex, Inc., PI, Calibration and performance of a non-invasive blood glucose meter
- 1998-99 Bristol-Myers Squibb, PI, Metformin XR monotherapy in type 2 diabetes
- 1998-99 Lilly, Co-Inv., 3.0 mL disposable pen study.
- 1998-99 Novo Nordisk, Inc., Co-Inv., Insulin and C-peptide responses to repaglinide in type 2 diabetes.
- 1998-99 SmithKline Beecham, PI, BRL49653C BID with glyburide in type 2 diabetes.
- 1999-01 Pfizer, Co-Inv., A study of inhaled human insulin monotherapy in type 2 diabetes.
- 1999-00 Bristol-Myers Squibb, PI, Fixed combination metformin/glyburide in T2DM.
- 1999-00 SmithKline Beecham, PI, Rosiglitazone/glyburide open label extension study
- 1999-00 SmithKline Beecham, PI, Rosiglitazone with glyburide and metformin in T2DM
- 1999-00 SmithKline Beecham, PI, Rosiglitazone with glipizide in elderly type 2 diabetes.
- 1999-00 Exocell, Co-Inv., Anti-glycation agent, EXO-226 on renal dysfunction in diabetic patients.
- 1999-00 Glaxo Wellcome, PI, GI262570 vs. glyburide or in combination in T2DM.
- 1999-00 Glaxo Wellcome, PI, GI262570 in combination with insulin in type 2 diabetes.
- 1999-00 Pfizer, Co-Inv., Long term safety of inhaled human insulin in type 1 or type 2 diabetes.

- 1999-00 Bristol Myers Squibb, PI, Rosiglitazone added to Metformin/Glyburide in T2DM.
- 1999-00 Bristol Myers Squibb, PI, Fixed combination metformin/glipizide in type 2 diabetes.
- 2000-01 Genzyme, Co-Inv., Diagnostic utility of Thyrogen®)-stimulated thyroglobulin for the surveillance of patients with treated papillary or follicular thyroid carcinoma.
- 2000-01 AstraZeneca, PI, Phase II study of AR-H039242 in patients with type 2 diabetes.
- 2001- Takeda, PI, Hepatic safety of pioglitazone vs. glyburide with metformin and insulin in T2DM
- 2001- Bristol Myers Squibb, PI, Omapatrilat CV treatment assessment versus enalapril (OCTAVE).
- 2001- BioStratum, PI, Pyridoxamine in nephropathy in Type 1 Diabetes
- 2001- BioStratum, PI, Pyridoxamine in nephropathy in Type 2 Diabetes
- 2002 Amylin, PI, Effect on glucose control of AC2993 given two times a day in subjects with type 2 diabetes mellitus treated with metformin or sulfonylurea or combination of met/SU.
- 2002 Aventis 4034, Co-Inv., Effect of Amaryl® in patients treated with Avandia® monotherapy.
- 2002 DepoMed, PI, Metformin ER tablets vs. metformin IR tablets in T2DM
- 2002 GlaxoSmithKline, Co-Inv., Effect of rosiglitazone on lipids in diabetic subjects taking statins.
- 2002 GlaxoSmithKline, PI, Carvedilol vs. metoprolol on glycemic control in hypertensive patients with type 2 diabetes mellitus.
- 2002 Hoffman LaRoche, Co-Inv., Efficacy, safety, tolerability and pharmacokinetics of RO 205 in patients with type 2 diabetes mellitus.
- 2002 Wyeth Ayerst, PI, Safety and efficacy of 4 doses of PTP-112 in patients with type 2 diabetes.
- 2002 Amylin Corp., PI, A phase 3, randomized, multicenter study of AC2993 given two times a day in subjects with Type 2 DM treated with Metformin alone.
- 2002 Amylin Corp., PI, A phase 3, randomized, multicenter study of AC2993 given two times a day in subjects with Type 2 DM treated with a sulfonylurea alone.
- 2001-03 Aventis, PI, Insulin glargine injection vs. pioglitazone (Actos) as add-on.
- 2002 Chugai Pharma, PI, A 12-week, placebo-controlled study to evaluate the safety and efficacy of GM-611 in patients with diabetic gastroparesis.
- 2002 Nutrition 21, PI, Chromium effects on insulin resistance and glycemic control in Type 2 DM
- 2000-03 Exocell, Co-inv., A double blind, randomized, multicenter, study of the effect of the anti-glycation agent, EXO-226, on renal dysfunction in two strata of albuminuric diabetic patients.
- 2002 Lilly, PI, Plasma adiponectin and glycemic control in Type 1 and Type 2 DM
- 2003 Merck, PI, Multicenter, double blind, randomized, active-controlled, parallel study in patients with Type 2 diabetes to evaluate the cardiac and metabolic effects of MK-0767.
- 2003 Merck, PI, Multicenter, randomized study of the addition of MK-0767 to patients with Type 2 DM on combined metformin and sulfonylurea therapy
- 2003 Merck, Co-inv., Double-blind, randomized, active-controlled MK-0767 and metformin comparator study in Type 2 diabetic patients inadequately controlled on diet and exercise
- 2003 GlaxoSmithKline, Co-inv., Multicenter, randomized, placebo controlled evaluation of rosiglitazone in combination with glimepiride in subjects with Type 2 DM
- 2004 Lilly, Co-inv., Global hypopituitary control and complications study (HypoCCS)
- 2004 Aventis, PI, ORIGIN: Insulin glargine/ ω -3 fatty acids in reducing cardiovascular morbidity and mortality in people with IFG, IGT or early T2DM
- 2004 NovoNordisk, PI, NovoLog® mix 70/30 BID with metformin and pioglitazone compared to metformin and pioglitazone alone in insulin-naïve subjects with T2DM
- 2004 KOWA, PI, Multicenter, randomized Phase IIA study of the addition of K-111 to patients with Type 2 DM suboptimally controlled on metformin therapy
- 2004-05 AstraZeneca, PI, Multicenter placebo-controlled study to evaluate tesaglitazar therapy in patients with type 2 diabetes mellitus poorly controlled on insulin (GALLANT 9)

2004-05 AstraZeneca, PI, Randomised, Multicenter, open label study to analyze renal mechanisms of creatinine excretion in patients on tesaglitazar (ARMOR)

2004-05 Sankyo, Co-Inv., Randomized, double-blind, placebo-controlled 12-week efficacy and safety study of CS-917 in patients with Type 2 Diabetes

2005-06 AstraZeneca, PI, Multicenter study of tesaglitazar therapy in patients with T2DM

2005-06 Thomas Jefferson University Hospital & Medtronic Minimed, Co-inv., Nocturnal glucose fluctuations with once daily glargine insulin vs. insulin pump therapy

2005- Merck, PI, Multicenter, randomized study of the co-administration of MK-0431 and metformin in patients with T2DM who have inadequate glycemic control

2005- AstraZeneca, PI, Open label multicenter, long-term extension study of tesaglitazar when added to insulin therapy in patients with T2DM

2006- Sanofi-Aventis, PI, AVE0010 (exendin-4 analog) with Metformin in T2DM

2006- ONO, PI, Phase IIa study of ONO-5129 (PPAR α/γ agonist) in treatment-naïve T2DM

2006- NovoNordisk, PI, Liraglutide safety and efficacy vs. Glimepiride in T2DM

2006- Mannkind, Co-Inv., Subcutaneous basal insulin and prandial inhalation of Technosphere® insulin vs. subcutaneous premixed insulin

2006- GlaxoSmithKline, Co-Inv., GW677954 (pan-PPAR agonist) monotherapy or add-on therapy with metformin in subjects with T2DM

2006- Sanofi-Aventis, PI, Rimonabant 20 mg daily for reducing risk of CV events in abdominally-obese patients with clustering risk factors (CRESCENDO)

2006- Bristol-Myers Squibb, PI, Saxagliptin (BMS-477118; DPP-IV inhibitor) in combination with TZD in patient with T2DM and inadequate glycemic control

2006- Sanofi-Aventis, PI, Dose-ranging study of AVE7688 in hypertension (ACE-NEP)

2006- Roche, Co-Inv., Phase 2 study of a glucokinase activator (RO4389620) in T2DM

2006- Boehringer, Co-Inv., Efficacy and safety of BI 1356 BS in T2DM

2006- Lifescan / Diabetech, PI, Facilitating Glycemic Control via Telemetric Acquisition and Computer-Assisted Compilation of Blood Glucose Data

2006- Merck, Co-Inv, Safety and efficacy of sitagliptin in elderly patients with T2DM

2006- NovoNordisk, PI, inhaled mealtime AERx insulin versus SC insulin aspart in combination with insulin detemir in T1DM

2006- Sanofi-Aventis, PI, AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus

2007- Merck, PI, Phase 3 trial of sitagliptin added to metformin and TZD in uncontrolled T2DM

2007- Takeda, PI, Efficacy and safety of SYR-322 with or without pioglitazone in T2DM subjects

2007- Merck, PI, Multicenter, randomized, double-blinded factorial study of the co-administration of sitagliptin and metformin in patients with T2DM

2007- Merck, PI, Phase 3 multicenter, randomized, double-blinded study of adding sitagliptin to T2DM patients with inadequate control on insulin (alone or in combination with metformin).

2007- Takeda, PI, Long-term, open-label extension study SYR-322 in T2DM

2007- NovoNordisk, Co-Inv., Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma

2007- Amylin Pharmaceuticals, Co-Inv., Basal Insulin Intensified With Either SYMLIN® or Rapid Acting Insulin in Patients With T2DM

2007- Lilly, Co-Inv., Durability of BD Insulin Lispro Low Mixture Compared to QD Insulin Glargine when added to Existing Oral Therapy in Patients with T2DM (DURABLE)

2007- Sanofi Aventis, PI. Glycemic Control with Rimonabant in Comparison with Glimepiride in Overweight/Obese T2DM Not Adequately Controlled with Metformin (Allegro)

2007- Daiichi Sankyo, PI, Rivoglitazone as Monotherapy Treatment of T2DM

Major Research Interests:

1. Mechanisms and regulation of insulin receptor signal transduction.
2. Protein-tyrosine phosphatases and the regulation of hormone action.
3. Pathophysiology of insulin-resistant disease states including obesity and Type 2 diabetes mellitus.
4. Mechanisms of the complications of diabetes, including vascular signaling by adiponectin

Major Administrative Responsibilities:

- 1985-86 Director, Employee Health Service, Highland Hospital, Rochester, NY
1989-92 Director, Enrichment Core Programs, Joslin Diabetes Center, Boston, MA
1993-96 Director of Research, Joslin Center for Diabetes *at Wills and Jefferson*, Philadelphia, PA
1992- Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
1992-2004 Program Director, Fellowship in Endocrinology, Diabetes and Metabolism, Thomas Jefferson University Hospital, Philadelphia, PA

Principal Clinical and Hospital Service Responsibilities:

- 1985-86 Medical Staff Physician, Highland Hospital, Rochester, NY
1989-92 Attending Physician, Diabetes and Metabolism, Brigham and Women's Hospital, Boston, MA
1992- Attending Physician, Endocrinology and Metabolism, Thomas Jefferson University Hospital
1994- Residency Candidate Interviewer, Thomas Jefferson University Hospital

Committee Activities:Thomas Jefferson University Hospital

- 1992- Bedside Glucose Quality Improvement Team
1992- Out-Patient Diabetes Education Program Advisory Committee
1994- Diabetes Therapy Working Group, Pharmacy and Therapeutics Committee
1997- Advisory Council for the Diabetes Self-Management Education Program

Jefferson Medical College

- 1993-94 Coordinator, Endocrinology/Metabolism/Diabetes Clinical Research Interest Groups
1993-97 Program in Nutrition Steering Committee
1993- Faculty Participant, Training Program in Clinical Pharmacology (Endocrinology)
1993- Member, Kimmel Cancer Institute
1994- Advisory Committee, Medical Scientist (MD, PhD) Training Program
Appointments and Promotions Committee, Department of Medicine
1997- Member
2006- Chairman
1999- Research Committee, Department of Medicine
1999-06 Clinical Competency Committee, Department of Medicine Residency Program
1999- Advisory Committee, Clinical Pharmacology Training Program in Human Investigation
2007- Executive Council, Clinical Science Representative

Thomas Jefferson University

- 1993- Molecular Pharmacology and Structural Biology, Ph.D. Candidate Thesis Committees (S. Parkinson, S. Deshmane, O. Goodman, D. Emlet)
1996- Pharmacology M.S. Thesis Committees (N. Sedkova, A. Zilbering, J. Zizzamia, L. Fuchsel)
1999- Physiology Ph.D. Thesis Committees (G. Booth, T. Stalker)
2003- Biochemistry and Molecular Pharmacology Ph.D. Thesis Committees (R. Drakas)

- 2004-05 Faculty Incentives for Research Productivity Committee
- 2004- Standing Committee on Conflicts of Interest and Commitment
- 2005 New Programs and Initiatives Committee
- 2006- Biomedical Chemistry M.S. Thesis Committee (A. Ochman)
- 2007- Molecular Pharmacology M.D./Ph.D. Thesis Committee Chair (B. DeGeorge)
- 2007- Biotechnology M.S. Thesis Committee (V. Patel)
- 2007- Intellectual Property Policy Committee
- 2007- Academic Tenure Committee

Teaching Experience:

- 1975-76 Teaching Assistant, Microbial Genetics, Cornell University, Ithaca, NY
- 1985-86 Ambulatory Medical Clinic, Highland Hospital, Rochester, NY
- 1988-92 Fellowship Program, Research Division, Joslin Diabetes Center
- 1989-92 Diabetes Consult Service, Brigham and Women's Hospital, Boston, MA
- 1989-92 Director, Longwood Area Diabetes/Metabolism Seminar Series, Harvard Medical School
- 1990 Harvard-Joslin Postgraduate Course on Type II Diabetes, Boston, MA
- 1990-91 Patient Lecture Series, Joslin Diabetes Center, Boston, MA
- 1990-91 Senior Thesis Reader, Harvard-M.I.T. Division of Health Sciences
- 1995 Program Director, 1995 Jefferson Endocrinology and Diabetes Symposium
- 1996 Program Director, National Diabetes Education Initiative Saturday Seminar, Philadelphia, PA

Jefferson Medical College Teaching Responsibilities

- 1992- Teaching Attending, Residency Program, Jefferson Medical College
- 1992- Fellowship Program in Endocrinology, Diabetes and Metabolism, TJUH
- 1992- Medical Residents Patient Management Conferences, Jefferson Medical College
- 1992- Biochemistry 100, Clinical Correlation Lectures on Diabetes Mellitus
- 1992 Introduction to Clinical Medicine, ICM 202: Physical Exam: Endocrinology Section
- 1993- Program in Nutrition Seminars, Management of the Diabetic Patient
- 1993- Pharmacology 401, Endocrine Disorders: Thyroid Gland and Adrenal Glands
- 1993- Pharmacology 522, Endocrine Systems: Insulin Action
- 1993-96 Co-Director, Pharmacology 702, Frontiers in Modern Endocrinology
- 1994- Primary Introduction to the Patient, ICM 203, Section Attending
- 1995- Molecular Pharmacology 680, Protein-tyrosine Phosphatases
- 1997- Doctor in Health and Illness: office-based experience for freshman students
- 1998 Clinico-Pathological Integrative Conference, Diabetic Retinopathy, Sophomore Class
- 2003 Scientific Foundations of Clinical Medicine, Review of Diabetes Mellitus for 4th year

ORIGINAL REPORTS

1. Goldstein BJ, Zahler SA. Uptake of branched chain α -keto acids in *Bacillus subtilis*. J Bacteriology 1976; **127**:667-670.
2. Zahler SA, Benjamin LG, Glatz BS, Winter PF, Goldstein BJ. Genetic mapping of *alsA*, *alsR*, *thyA*, *kauA*, and *citD* Markers in *Bacillus subtilis*. In: Schlessinger D, ed. **Microbiology 1976**. American Society for Microbiology: Washington, D.C., 1976; PP. 35-43.
3. Goldstein BJ, Livingston JN. Effects in adipocytes of diamide on GSH levels, glucose uptake and cell integrity. Biochim Biophys Acta 1978; **513**:99-105
4. Goldstein BJ, Livingston JN. Insulin degradation by adipose tissue: Studies at several levels of cellular organization. Biochem J 1980; **186**:351-360
5. Goldstein BJ. Insulin degradation by adipocytes: Significance of neutral cytosol protease activity. Ph.D. Thesis, University of Rochester School of Medicine and Dentistry, 1980.
6. Goldstein BJ, Livingston JN. An evaluation of the importance of lysosomal and neutral cytosol proteases in insulin degradation by adipocytes. Endocrinology 1981; **108**:953-961
7. Goldstein BJ, Hanna K, Bullous skin ulceration in a man with myelofibrosis. Hospital Practice 1986; **21**:102-104.
8. Goldstein BJ, Mushlin AI. Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism. J Gen Intern Med 1987;**2**:20-24.
9. Goldstein BJ, Müller-Wieland D, Kahn CR. Variation in insulin receptor messenger ribonucleic acid expression in human and rodent tissues. Molecular Endocrinology 1987; **1**:759-766.
10. Ludwig S, Müller-Wieland D, Goldstein BJ, Kahn CR. The insulin receptor gene and its expression in insulin-resistant mice. Endocrinology 1988; **123**:594-600.
11. Goldstein BJ, Kahn CR. Initial processing of the insulin receptor precursor *in vivo* and *in vitro*. J Biol Chem 1988; **263**:12809-12812.
12. Kwok CG, Goldstein BJ, Müller-Wieland D, Lee TS, Kahn CR, King GL. Identification of persistent defects in insulin receptor structure and function in capillary endothelial cells from diabetic BB rats. J Clin Invest 1989; **83**:127-136.
13. Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: Application to the insulin receptor. Biochem Biophys Res Comm 1989; **159**:664-669.
14. Goldstein BJ, Kahn CR. Insulin receptor messenger RNA sequence alterations detected by ribonuclease cleavage in patients with syndromes of insulin resistance. J Clin Endocrinol Metab 1989; **69**:15-24.
15. Goldstein BJ, Dudley AL. The rat insulin receptor: Primary structure and conservation of tissue-specific alternative messenger RNA splicing. Molecular Endocrinology 1990; **4**:235-244.
16. Davison G, Suchman AL, Goldstein BJ. Reducing unnecessary coronary care unit admission: a comparison of three decision aids. J Gen Intern Med 1990; **5**:474-479.
17. Goldstein BJ, Dudley AL. Molecular heterogeneity of insulin receptors in rat tissues. Adv Exp Med Biol 1991; **293**:187-195.
18. Goldstein BJ, Meyerovitch J, Zhang W-R, Backer JM, Csermely P, Hashimoto N, Kahn CR. Hepatic protein-tyrosine phosphatases and their regulation in diabetes. Advances in Protein Phosphatases 1991; **6**:1-17.
19. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden P, Cahill DA, Goldstein BJ, White MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; **352**:73-77.
20. Zhang W-R, Goldstein BJ. Identification of skeletal muscle protein-tyrosine phosphatases by amplification of conserved cDNA sequences. Biochem Biophys Res Comm 1991; **178**:1291-1297.

21. Goldstein BJ, Zhang W-R, Hashimoto N, Kahn CR. Approaches to the molecular cloning of protein-tyrosine phosphatases in insulin-sensitive tissues. *Mol Cell Biochem* 1992; **109**:107-113.
22. Hashimoto N, Zhang W-R, Goldstein BJ. Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. *Biochem J* 1992; **284**:569-576.
23. Chatterjee S, Goldstein BJ, Csermely P, Shoelson SE. Design and synthesis of potent substrates and inhibitors of protein-tyrosine phosphatases. In: Rivier JE, Smith JA, eds. **Peptides: Chemistry and Biology**. Escam Science Publishers, Leiden, Netherlands. 1992; pp. 553-555.
24. Goldstein BJ, Dudley AL. Heterogeneity of messenger RNA encoding the rat insulin receptor is limited to the domain of exon 11. Analysis by RNA heteroduplex mapping, amplification of cDNA and in vitro translation. *Diabetes* 1992; **41**:1293-1300.
25. Hashimoto N, Feener EP, Zhang W-R, Goldstein BJ. Insulin receptor protein-tyrosine phosphatases: Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. *J Biol Chem* 1992; **267**:13811-13814.
26. Hashimoto N, Goldstein BJ. Differential regulation of mRNAs encoding three protein tyrosine phosphatases by insulin and activation of protein kinase C. *Biochem Biophys Res Comm* 1992; **188**:1305-1311.
27. Kriauciunas KM, Goldstein BJ, Lipes MA, Kahn CR. Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines. *J Cellular Physiology* 1993; **154**:486-495.
28. Baskin DG, Schwartz MW, Sipols AJ, D'Alessio DA, Goldstein BJ, White MF. Insulin receptor substrate-1 (IRS-1) expression in rat brain. *Endocrinology* 1994; **134**:1952-1955.
29. Zhang W-R, Hashimoto N, Ahmad F, Ding W, Goldstein BJ. Molecular cloning and expression of a unique receptor-like protein-tyrosine phosphatase in the leukocyte common antigen-related (LAR) phosphatase family. *Biochem. J.* 1994; **302**:39-47.
30. Rotin D, Goldstein BJ, Fladd CA. Expression of the protein-tyrosine phosphatase LAR-PTP2 is developmentally regulated in lung epithelia. *Am. J. of Physiol* 1994; **267**:L263-270.
31. Ding W, Zhang WR, Sullivan K, Hashimoto N, Goldstein BJ. Identification of protein-tyrosine phosphatases prevalent in adipocytes by molecular cloning. *Biochem. Biophys. Res. Comm.* 1994; **202**:902-907.
32. Ahmad F, Goldstein BJ. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of obesity and insulin resistant diabetes mellitus. *Metabolism* 1995; **44**:1175-1184.
33. Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is augmented by antisense inhibition of the protein-tyrosine phosphatase LAR. *J. Biol. Chem.* 1995; **270**:2435-2438.
34. Ahmad F, Goldstein BJ. Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue. *Biochim. Biophys. Acta*, 1995; **1248**:57-69.
35. Ahmad F, Goldstein BJ. Alterations in specific protein-tyrosine phosphatases accompany the insulin resistance of streptozotocin-diabetes. *Am. J. Physiol.* 1995; **268**:E932-E940.
36. Ahmad F, Considine R, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. *J. Clin. Invest.* 1995; **95**:2806-2812.
37. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ. Osmotic loading of neutralizing antibodies demonstrates a role for PTPase1B in negative regulation of the insulin action pathway. *J. Biol. Chem.* 1995; **270**:20503-20508.

38. Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. *J. Biol. Chem.* 1996; **271**:748-754.
39. Li PM, Goldstein BJ. Cell density-dependent changes in the insulin action pathway: Evidence for involvement of protein-tyrosine phosphatases. *J. Cellular Biochem.* 1996; **61**:31-38.
40. Kim H, Yeger H, Han R, Goldstein BJ, Rotin D. Expression of the tyrosine phosphatase LAR-PTP2 in rat lung is developmentally regulated and confined to undifferentiated epithelia lining the airways and air sac. *Am. J. Physiol.* 1996; **270**:L566-L576.
41. Zhang W-R, Li P-M, Oswald MA, Goldstein BJ. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. *Mol. Endocrinol.* 1996; **10**:575-584.
42. Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. *Cellular Signaling* 1996; **8**: 467-473.
43. Li PM, Goldstein BJ. Differential regulation of insulin-stimulated tyrosine phosphorylation of IRS-1 and Shc by wortmannin in intact cells. *Biochem. Biophys. Res. Comm.*, 1996; **223**:80-84.
44. Saito S, Hashimoto N, Tokita K, Toyoda M, Suzuki Y, Goldstein BJ, Suzuki H, Makino H, Saito Y. Changes in expression of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene. *Biochem. Biophys. Res. Comm.* 1996; **227**:406-412.
45. Ahmad F, Goldstein BJ. Effect of tumor necrosis factor- α on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. *J. Cellular Biochem.* 1997; **64**:117-127.
46. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. *J. Biol. Chem.* 1997; **272**:448-457.
47. Ahmad F, Azevedo J, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes, *J. Clin. Invest.* 1997; **100**:449-458.
48. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. *Metabolism* 1997; **46**:1140-1145.
49. Kolaczynski JW, Goldstein BJ, Considine RV. Dexamethasone, OB gene and leptin in humans: Effect of exogenous hyperinsulinemia. *J. Clin Endocrinol. Metab.* 1997; **82**:3895-3897.
50. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW and the Troglitazone Study Group troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. *J Clin Endocrinol Metab* 1998; **83**:3169-3176
51. Ren JM, Li PM, Zhang WR, Sweet LJ, Cline G, Shulman GI, Livingston JN, Goldstein BJ. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. *Diabetes* 1998;**47**:493-497.
52. Kole HK, Kole S, Mallory BP, Li PM, Goldstein BJ, Bernier M. Inhibition of the transmembrane PTPase LAR by 3S-peptide-I enhances insulin receptor phosphorylation in intact cells. *Revs Clin Basic Pharmacol* 1998; **9**:2-4.
53. Ohannesian JP, Marco CC, Najm PS, Goldstein BJ, Caro JF, Kolaczynski JW. Small weight gain is not associated with development of insulin resistance in healthy, physically active individuals. *Horm. Metab. Res.* 1999; **31**:323-325.
54. Diabetes Prevention Program Study Group. The Diabetes Prevention Program: Design and Methods for a Clinical Trial in the Prevention of Type 2 Diabetes Mellitus. *Diabetes Care* 1999;**22**:623-634.
55. Toyoda M, Hashimoto N, Tokita K, Goldstein BJ, Yokosuka O, Kanatsuka A, Suzuki Y , Saito Y. Increased activity and expression of MAP kinase in HCC model rats induced by 3-methyl-4-dimethylamino-azobenzene. *J Hepatology* 1999; **31**:725-733.

56. Solow BT, Harada S, Goldstein BJ, Smith JA, White MF, Jarett L. Differential modulation of the tyrosine phosphorylation state of the insulin receptor by IRS Proteins. *Mol Endo* 1999; **13**: 1784 – 1798.
57. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. *J Clin Pharm* 2000; **40**:49-57.
58. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adapter protein, *J. Biol. Chem* 2000; **275**:4283-4289.
59. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky G, Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin dependent diabetes mellitus: in vivo and in vitro studies. *Metabolism* 2000; **49**:400-410.
60. Diabetes Prevention Program Study Group. The Diabetes Prevention Program: Baseline Characteristics of the Randomized Cohort. *Diabetes Care* 2000; **11**:1619-1629.
61. Tang S, Le-Tien H, Goldstein BJ, Shin P, Lai R, Fantus IG. Decreased insulin receptor dephosphorylation in hyperglycemia and hyperinsulinemia-induced insulin resistance in rat adipocytes is associated with decreased LAR protein tyrosine phosphatase content and activity. *Diabetes* 2001; **50**:83-90.
62. Zhu L, Zilbering A, Wu X, Mahadev K, Joseph JI, Jabbour S, Deeb W, Goldstein BJ. Use of an Anaerobic Environment to Preserve the Endogenous Activity of Protein-Tyrosine Phosphatases Isolated from Intact Cells. *FASEB J* 2001;**15**:1637-1639. *FASEB J* express article published online 10.1096/fj.00-0795fje.
63. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-Stimulated Hydrogen Peroxide Reversibly Inhibits Protein-Tyrosine Phosphatase 1B *in vivo* and Enhances the Early Insulin Action Cascade, *J. Biol. Chem* 2001;**276**:21938-21942.
64. Goldstein BJ, Zhu L, Hager R, Zilbering A, Sun Y, Vincent JB. Enhancement of Post-Receptor Insulin Signaling by Trivalent Chromium in Hepatoma Cells May Involve Differential Inhibition of Specific Protein-Tyrosine Phosphatases. *J Trace Elements Exp Med* 2001;**14**:393-404.
65. Wu X, Hoffstedt J, Deeb W, Singh R, Sedkova N, Zilbering A, Zhu L, Park PK, Arner P, Goldstein BJ. Depot-Specific Variation in Protein-Tyrosine Phosphatase Activities in Human Omental and Subcutaneous Adipose Tissue: A Potential Contribution to Differential Insulin Sensitivity. *J Clin Endocrinol Metab* 2001;**86**:5973-5980.
66. Mahadev K, Wu X, Zilbering A, Zhu L, Lawrence JTR, Goldstein BJ. Hydrogen Peroxide Generated During Cellular Insulin Stimulation Is Integral to Activation of the Distal Insulin Signaling Cascade in 3T3-L1 Adipocytes, *J. Biol. Chem* 2001; **276**:48662-48669.
67. Torjman MC, Jahn L, Joseph JI, Crothall K, Goldstein BJ. Accuracy of the Hemocue Portable Glucose Analyzer in a Large Non-Homogeneous Population. *Diabetes Technology & Therapeutics* 2001; **3**:591-600.
68. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Recruitment Methods and Results. *Controlled Clinical Trials* 2002; **23**:157-171.
69. Zhu L, Goldstein BJ. Use of an Anaerobic Chamber Environment for the Assay of Endogenous Cellular Protein-Tyrosine Phosphatase Activities. *Biol. Proc. Online* 2002; **4**:1-9.
70. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *N Engl J Med* 2002; **346**:393-403.
71. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential Regulation of Adiponectin Secretion by Cultured Human Omental and Subcutaneous Adipocytes: Effects of Insulin and Rosiglitazone. *J Clin Endocrinol Metab* 2002; **87**:5662-5667.
72. Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the Metabolic Effects of Rosiglitazone Influenced by Baseline Glycemic Control?, *Curr Med Res Opin*, 2003; **19**:192–199.

73. The Diabetes Prevention Program Research Group. Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program. *Diabetes Care* 2003;**26**:977-980.
74. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated Protein Kinase in Glucose Uptake Stimulated by Adiponectin in Primary Rat Adipocytes, *Diabetes* 2003; **52**:1355–1363.
75. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin therapy as second-line pharmacologic treatment for patients with type 2 diabetes that is inadequately controlled by a sulfonylurea. *Clin Ther* 2003; **25**:890-903.
76. Wu X, Hardy VE, Joseph JJ, Jabbour S, Mahadev K, Zhu L Goldstein BJ. Protein-Tyrosine Phosphatase Activity in Human Adipocytes is Strongly Correlated with Insulin-Stimulated Glucose Uptake and is a Target of Insulin-Induced Oxidative Inhibition. *Metabolism* 2003;**52**:705-712.
77. Mazurek T, Zhang LF, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Martella A, Goldstein BJ, Shi Y. Human Epicardial Adipose Tissue is a Source of Inflammatory Mediators. *Circulation* 2003;**108**:2460-2466.
78. Mahadev K, Wu X, Motoshima H, Goldstein BJ. Integration of Multiple Downstream Signals Determines the Net Effect of Insulin on MAP Kinase vs. PI 3'-Kinase Activation: Potential Role of Insulin-Stimulated H₂O₂. *Cell Signal*. 2004;**16**:323-331.
79. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, Goldstein BJ. The NADPH Oxidase Homolog Nox4 Modulates Insulin-Stimulated Generation of H₂O₂ and Plays an Integral Role in Insulin Signal Transduction. *Mol Cell Biol*, 2004;**24**:1844-1854.
80. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. *Biochem Biophys Res Comm*, 2004;**315**:264-271.
81. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular (CVD) risk factors in the Diabetes Prevention Program. *Diabetes Care* 2005;**28**:888-94.
82. Wu XD, Zhu L, Zilbering A, Mahadev K, Motoshima H, Yao, JL, Goldstein BJ. Hyperglycemia Potentiates H₂O₂ Production in Adipocytes and Enhances Insulin Signal Transduction: Potential Role for Oxidative Inhibition of Thiol-Sensitive Protein-Tyrosine Phosphatases. *Antioxidants & Redox Signaling*, 2005;**7**:526-537.
83. Hu T, Ramachandra Rao S, Siva S, Valancius C, Zhu Y, Mahadev K, Toh I, Goldstein BJ, Woolkalis M, Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-β induced cytoskeletal alterations in endothelial cells, *Am J Physiol Renal Physiol* 2005;**289**:F816-F825.
84. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz A, Wooddell MJ, Strow LJ. The EMPIRE Study: Benefits of Rosiglitazone added to Submaximal doses of Metformin compared with Dose Escalation of Metformin in Type 2 Diabetes, *Curr Med Res Opin*, 2005;**21**:2029-35.
85. Rosenstock J, Goldstein BJ, Vinik AI, O'Neill C, Porter L, Heise MA, Kravitz B, Dirani R, Freed MI, and the RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. *Diabetes, Obesity and Metabolism*, 2006;**8**:49-57.
86. Ouedraogo R, Motoshima H, Wu XD, Mahadev K, Hough K, Scalia R, Goldstein BJ. Adiponectin Suppression of High Glucose-Induced Reactive Oxygen Species in Vascular Endothelial Cells: Evidence for Involvement of a cAMP Signaling Pathway. *Diabetes*, 2006;**55**:1840-1846.
87. Goldstein BJ, Weissman P, Wooddell MJ, Waterhouse BR, Strow LJ. Reductions in Biomarkers of Cardiovascular Risk in Type 2 Diabetes with Rosiglitazone Added to Metformin compared with Dose Escalation of Metformin: An EMPIRE Trial Substudy. *Curr Med Res Opin*. 2006;**22**:1715–1723.
88. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman KP. Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. *Curr Med Res Opin*, 2006;**22**:2575–2590

89. Patel DN, Bailey, SR, Gresham JK, Schuchman DB, Shelhamer JH, Goldstein BJ, Foxwell BM, Stemerman MB; Maranchie JK, Valente AJ, Mummidi S, Chandrasekar B. TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells. *BBRC*, 2006;**347**:1113-1120.
90. Nathan DM, Chew E, Christophi CA, Davis MD, Fowler S, Goldstein BJ, Hamman RF, Hubbard LD, Knowler WC, Molitch ME for the Diabetes Prevention Program research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabetic Medicine* 2007;**24**:137-144.
91. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher T, Lopez B, Koch W, Chan L, Goldstein BJ, Ma XL. Adiponectin Cardioprotection following Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress. *Circulation* 2007;**115**:1408-1416.
92. Ouedraogo R, Gong Y, Berzins B, Wu XD, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia RG. Adiponectin Deficiency Increases Leukocyte-Endothelium Interactions via Upregulation of Endothelial Cell Adhesion Molecules In Vivo. *J Clin Invest* 2007;**117**:1718-26.
93. Goldstein BJ, Feinglos MN, Luncford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care*, 2997, *in press*.
94. Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. *Diabetes, Obesity and Metabolism*, *in press*.
95. Rosenzweig SA, Reibel DK, Greeson JM, Edman JS, Jasser SA, McMearty KD, Goldstein BJ. Mindfulness-Based Stress Reduction is Associated with Improved Glycemic Control in Type 2 Diabetes Mellitus: A Pilot Study. *Altern Ther Health Med* 2007; **13**:36-38.
96. Li R, Wang W-Q, Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F, Ma X-L. Adiponectin Improves Endothelial Function in Hyperlipidemic Rats by Reducing Oxidative/Nitrative Stress and Differential Regulation of eNOS/iNOS Activity, *Am J Physiol Endocrinol Metab*. published 25 September 2007; 10.1152/ajpendo.00462.2007

REVIEWS, CHAPTERS AND EDITORIALS

1. Goldstein BJ, Livingston JN. Progress in Endocrinology and Metabolism: Insulin degradation by insulin target cells. *Metabolism* 1981; **30**:825-835.
2. Goldstein BJ, Kahn CR. Insulin allergy and insulin resistance. In: Lichtenstein LM, Fauci AS, eds. **Current Therapy in Allergy, Immunology and Rheumatology**. Lewiston, NY; B.C. Decker, Inc. 1988; pp, 327-330.
3. Kahn CR, Goldstein BJ, Shoelson SE. Mechanisms of insulin receptor activation and biosynthesis. In Imura H, Shizume K, Yoshida S, eds. **Progress in Endocrinology 1988**. Amsterdam: Elsevier Science Publishers B.V. 1988; pp. 371-376.
4. Kahn CR, Goldstein BJ. Perspective: Molecular defects in insulin action. *Science* 1989; **245**:13
5. Kahn CR, Goldstein BJ, Reddy SSK. Hereditary and acquired syndromes of insulin resistance. In: Pickup J, Williams G, eds. **Textbook of Diabetes**. Oxford, England: Blackwell Scientific Publications, Ltd. 1991; pp. 276-285
6. Goldstein BJ. Protein-tyrosine phosphatases and the regulation of insulin action. *J Cell Biochem* 1992; **48**:33-42.
7. Goldstein BJ, Kahn CR. Insulin receptors in normal and disease states. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. **International Textbook of Diabetes Mellitus**. Sussex, England: John Wiley & Sons, Ltd. 1992; pp. 357-383.

8. Manning WJ, Goldberger AL, Drews RE, Goldstein BJ, Matheson JK, Rabinowe SL, Trentham DE, Landsberg L. POEMS syndrome with myocardial infarction: observations concerning pathogenesis and review of the literature. *Sem Arthr Rheum* 1992; **22**:151-161.
9. Goldstein BJ. The menopause and diabetes: Exploring the connection. *Menopause Management*, February, 1993, pp. 16-19.
10. Kahn CR, White MF, Shoelson SE, Backer J, Araki E, Cheatham B, Siddle K, Sun XJ, Wilden P, Yamada K, Csermely P, Folli F, Goldstein BJ, Huertas P, Rothenberg PL, Saad MJ. The insulin receptor and its substrate: Molecular determinant of early events in insulin action. In: Bardin CW, ed. **Recent Progress in Hormone Research**, Vol. 48. Orlando: Academic Press. 1993; pp. 291-339.
11. Goldstein BJ Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. *Receptor* 1993; 3:1-15.
12. Goldstein BJ. Syndromes of extreme insulin resistance. In: Weir GC, Kahn CR, eds. **Joslin's Diabetes Mellitus**, 13th edition. Philadelphia: Lea & Febiger. 1994; pp. 282-299.
13. Goldstein BJ. Protein-tyrosine phosphatases and the regulation of insulin action. In: LeRoith D, Olefsky JM, Taylor SI, eds. **Diabetes Mellitus: A Fundamental and Clinical Text**. Philadelphia, PA: JB Lippincott Co. 1996, pp. 174-186.
14. Garber AJ, Gavin JR III, Goldstein BJ. Insulin resistance, syndrome X, and type II diabetes. *Patient Care*, June 15, 1996, pp.198-211.
15. Kolaczynski JW, Goldstein BJ. Glycation of hemoglobin and serum proteins as tools for monitoring. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. **International Textbook of Diabetes Mellitus**, 2nd edition. Sussex, England: John Wiley & Sons, Ltd. 1997.
16. Maratos-Flier E, Goldstein BJ, Kahn CR. The insulin receptor and postreceptor mechanisms. In: Pickup J, Williams G, eds. **Textbook of Diabetes**, 2nd edition. Oxford, England: Blackwell Scientific Publications, Ltd. 1997, pp 10.1-10.22.
17. Goldstein BJ. Three clinical case scenarios: "Compounded Confusion", "Amenorrhea and Galactorrhea", and "Weak and Shaky Spells." In: Cutler P, ed. **Problem Solving in Clinical Medicine: From Data to Diagnosis**, 3rd ed. Baltimore, MD: Williams & Wilkins, 1998, pp 202-212.
18. Goldstein BJ, Ahmad F, Ding W, Li PM, Zhang WR. Regulation of the insulin signaling pathway by cellular protein-tyrosine phosphatases. *Mol Cell Endocrinol*, 1998; **182**:91-99.
19. Goldstein BJ, Li PM, Ding W, Ahmad F, Zhang WR. Regulation of insulin action by protein-tyrosine phosphatases. *Vitamins and Hormones*, vol. 54, 1998, pp. 67-96.
20. Peters AL, Henry R, Edelman SV, Goldstein BJ. Keep metformin guidelines intact (Letter). *Diabetes Care* 22: 532, 1999.
21. Goldstein BJ. Treatment of Type 2 Diabetes: Efficacy of Thiazolidinediones as Monotherapy. *Consultant* 39:S21-S27, 1999.
22. Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. *Diabetes Technology & Therapeutics* 1:267-275, 1999.
23. Goldstein BJ, Wiegers SE. Treatment Strategies for Type 2 Diabetes: Anti-Hyperglycemics and Cardiovascular Protection. *Drug Benefit Trends* 11(Suppl. B):11-34, 1999.
24. Goldstein BJ. Epidemiology and Pathogenesis of Type 2 Diabetes. In: *Managed Care Interface*, 1999, Medicom International, Inc., Bronxville, NY.
25. Kolaczynski JW, Goldstein BJ. The influence of obesity on the development of non-insulin-dependent diabetes mellitus. In: **Obesity: Pathology and Therapy**, edited by D. H. Lockwood and T. G. Heffner, *Handbook of Experimental Pharmacology*, Volume 149, New York:Springer-Verlag, 2000, p. 91-119.

26. Goldstein BJ. Regulation of insulin action by protein-tyrosine phosphatases. In: LeRoith D, Olefsky JM, Taylor SI, eds. **Diabetes Mellitus: A Fundamental and Clinical Text**. 2nd Edition. Philadelphia, PA: JB Lippincott Co. 2000, pp. 206-217.
27. Goldstein BJ. Drug Focus: Rosiglitazone. *Int J Clin Prac*, 2000; **54**(5):333-337.
28. Jabbour SA, Goldstein BJ. Improving Disease Management with New Treatments for Type 2 Diabetes. *Clinical Geriatrics*, 2000; **8**:44-56.
29. Goldstein BJ. Hyperinsulinemia in the Insulin Resistance Syndrome: Should it be the Target of Treatment? *Diab Rel Dis Newsletter*, September 2000.
30. Jabbour SA, Goldstein BJ. Improving Disease Management with New Treatments for Type 2 Diabetes Mellitus. *Clinical Geriatrics*, Special issue on Geriatric Prescribing Options, 2001; **9**:57-68.
31. Singh R, Wieggers S, Goldstein BJ. The Impact of Gender on Diabetes Mellitus and its Associated Cardiovascular Risk Factors. *Clinical Geriatrics*, 2001; **9**:63-70.
32. Singh R, Wieggers S, Goldstein BJ. The Impact of Gender on Diabetes Mellitus and its Associated Cardiovascular Risk Factors. *Journal of Gender-Specific Medicine*, 2001; **4**:28-36.
33. Goldstein BJ. Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2 Diabetes Mellitus, Obesity and Related States of Insulin Resistance. *Current Drug Targets in Immune, Endocrine and Metabolic Disorders*, 2001; **1**:265-275.
34. Goldstein BJ. Insights from mouse models deficient in protein-tyrosine phosphatases that regulate the insulin action pathway. In: Grunberger G, Zick Y, guest eds. **Insulin Signaling: From Cultured Cells to Animal Models**. Oxford, England: Harwood Academic Press 2002, pp 35-50.
35. Goldstein BJ. Differentiating Members of the Thiazolidinedione Class: a Focus on Efficacy. *Diabetes Metab. Res. Rev.* 2002; **18**:S16-S22.
36. Goldstein BJ. Protein-Tyrosine Phosphatases: Emerging Targets for Therapeutic Intervention in Type 2 Diabetes and Related States of Insulin Resistance. *J Clin Endocrinol Metab* 2002; **87**:2474–2480.
37. Goldstein BJ. Possible Vascular-Protective Effects of Antidiabetic Agents Such as the Thiazolidinediones (Letter). *Clin Ther* 2002; **24**:1358-60.
38. Goldstein BJ. Pathogenesis of Type 2 Diabetes Mellitus: Insulin Resistance is a Core Defect..*Am J Cardiol* 2002; **90**(suppl):3G-10G.
39. Goldstein BJ. Diabetes Mellitus. In: Rubin E, ed. **Pathology**. Philadelphia: Lippincott-Williams & Wilkins, 2003.
40. Goldstein BJ. Diabetes Mellitus. In: Gonnella JS, ed. **Disease staging : clinical criteria**, 5th ed. 2003.
41. Müller-Wieland D, Kotzka J, Goldstein BJ. Pathogenesis of type 2 diabetes. In: Goldstein BJ, Müller-Wieland D, Eds. **Textbook of Type 2 Diabetes**. London: Martin Dunitz, 2003, pp. 13-28.
42. Jabbour SA, Goldstein BJ. Type 2 Diabetes: Geriatric Considerations. In: Goldstein BJ, Müller-Wieland D, Eds. **Textbook of Type 2 Diabetes**. London: Martin Dunitz, 2003, pp. 409-422.
43. Joseph JJ, Goldstein BJ. New Devices and Drugs on the Horizon. In: Goldstein BJ, Müller-Wieland D, Eds. **Textbook of Type 2 Diabetes**. London: Martin Dunitz, 2003, pp. 447-460.
44. Goldstein BJ. Regulation of insulin action by protein-tyrosine phosphatases. In: LeRoith D, Olefsky JM, Taylor SI, eds. **Diabetes Mellitus: A Fundamental and Clinical Text**. 3rd Edition. Philadelphia, PA: JB Lippincott Co. 2003.
45. Goldstein BJ, Jabbour S, Ahmed I. Glycated hemoglobin and serum proteins as tools for monitoring. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. **International Textbook of Diabetes Mellitus**, 3rd edition. Sussex, England: John Wiley & Sons, Ltd. 2003.
46. Goldstein BJ. Insulin Resistance: From Benign to Type 2 Diabetes Mellitus. *Rev Cardiovasc Med* 2003; **4**(Suppl 6): S3-S10.

47. Goldstein BJ, Scalia R. Adiponectin: A Novel ‘Adipokine’ Linking Adipocytes and Vascular Function, *J Clin Endocrinol Metab*, 2004;**89**:2563-2568.
48. Jabbour S, Anolik J, Goldstein BJ. Insulin-Sensitizing and Insulin-Sparing Drugs: Thiazolidinediones and Metformin. In: Fonseca V, ed. *Clinical Diabetes: Translating Research into Practice*. Philadelphia: Elsevier, 2005.
49. Goldstein BJ, Kalyanar M, Wu XD. *Redox Paradox*: Insulin Action is Facilitated by Insulin-Stimulated Reactive Oxygen Species with Multiple Potential Signaling Targets. *Diabetes* 2005;54:311-321.
50. Stumvoll M, Goldstein BJ, van Haeften, TW. Seminar: Type 2 Diabetes: – Principles of Pathogenesis and Therapy. *Lancet* 2005;365:1333–46.
51. Goldstein BJ, Ahmed I. “Inflammatory” Signaling: Bridging Obesity-Linked Insulin Resistance with Vascular Dysfunction. *Diabetes und Stoffwechsel (German Diabetes Assoc. Journal)* 2005;14:31-36.
52. Goldstein BJ, Ahmed I. Adiponectin: A New Hormone From Fat Cells (concise review). In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ (eds), *harrisonsonline.com*. New York: McGraw-Hill, 2005.
53. Rosenberg D, Jabbour SA, Goldstein BJ. Insulin Resistance, Diabetes, and Cardiovascular Risk: Approaches to Treatment. *Diabetes, Obesity and Metabolism*, 2005;**7**:642-653.
54. Goldstein BJ, Mahadev K, Wu XD, Zhu L, Motoshima H. Role of Insulin-Induced Reactive Oxygen Species in the Insulin Signaling Pathway. *Antioxidants and Redox Signaling*, 2005;**7**:1021-31.
55. Goldstein BJ. Intensive insulin therapy regimens: is there a difference in patient satisfaction? *Nature Clin Pract Endocrinol Metab*, 2005;1:80-81 (doi:10.1038/ncpendmet0054)
56. Goldstein BJ. Structure and Function of the Insulin Receptor. UpToDate (www.uptodate.com).
57. Goldstein BJ. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes? *Int J Clin Pract* 2006;**60**:873-83
58. Ahmed I, Goldstein BJ. Cardiovascular Risk in the Spectrum of Type 2 Diabetes Mellitus. *Mount Sinai J Med*, 2006;**73**:759-68.
59. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and Cell Proliferation: AMPK as a Therapeutic Target for Atherosclerosis and Cancer, *J Physiol*, 2006;**574**:63-71.
60. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes. *Am J Therapeutics*, 2007;**14**:49-62.
61. Goldstein BJ, Scalia R. Adipokines and Vascular Disease in Diabetes. *Curr Diab Rep*, 2007;**7**:25–33.
62. Goldstein BJ. Clinical Translation of “A Diabetes Outcome Progression Trial”: ADOPT Appropriate Combination Oral Therapies in Type 2 Diabetes. *J Clin Endocrinol Metab*, 2007;**92**:1226–1228.
63. Goldstein BJ, Mahadev K, Wu XD. Insulin-Stimulated Reactive Oxygen Species and Insulin Signal Transduction. In: Packer L, Sies H, eds. *Oxidative Stress and Inflammatory Mechanisms in Obesity, Diabetes, and the Metabolic Syndrome*. pp 178-187. Boca Raton, FL: Taylor and Francis, 2007.
64. Goldstein BJ, Scalia R, Ma XL, Mahadev K, Wu XD, Ouedraogo R. Letter to the Editor of DIABETES re: Hattori et al. Globular Adiponectin Activates Nuclear Factor- $\{\kappa\}$ B and Activating Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. *Diabetes* 56:804-808, 2007.

MONOGRAPHS / BOOKS

1. Goldstein BJ. Phosphoprotein Phosphatases 1: Tyrosine Phosphatases. Volume 2, issue 13 *In Protein Profile*, Sheterline P, series ed., London:Academic Press, 1995; pp.1425-1585.
2. Goldstein BJ, Kirchain WR, eds., *Diabetes: Approaches in Disease Management*, CMR Institute, Roanoke, VA, 1997

3. Goldstein BJ. Tyrosine Phosphoprotein Phosphatases. 2nd edition, *In Protein Profile*, Sheterline P, series ed., London:Oxford University Press, 1998.
4. Goldstein BJ, Cotter VT, Morley JE, Setter SM. Type 2 Diabetes in the Long-Term Care Environment: A Practical Approach To Patient Care. Medical Education Systems, 1998.
5. Wender R, Caro J, Goldstein BJ, Plent S, eds. Caring for Diabetes: Evaluation and Management of Diabetes. CME monograph. Philadelphia: Aetna/USHealthcare, 1998.
6. Goldstein BJ, Gorstein F, Guest Editors. "Diabetes Mellitus", Clinics in Laboratory Medicine, Philadelphia: Saunders, 2001.
7. Goldstein BJ, Guest Editor. A Symposium: Evolution of Type 2 Diabetes Management: Assessment and Clinical Application of Newer Findings. Suppl. to Am J Cardiol 2002;90(suppl):1G-50G.
8. Lenow JL, Capuzzi DM, Goldstein BJ, Morgan J. Recent Advances in the Treatment of Dyslipidemia in Patients with Type 2 Diabetes: Focus on Fibrate Therapy. CME monograph. Philadelphia: Jefferson Medical College, Thomas Jefferson University, 2003.
9. Goldstein BJ, Müller-Wieland D, Eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003.
10. Goldstein BJ, Hendrickson J, Rodriguez MR. Diabetes Management, module 2. Medication Therapy Management Services: Applying Compliance and Adherence Principles to Optimize Care of Patients with Diabetes. CE monograph for the American Pharmacists Association (AP'hA), 2006.

GenBank SUBMISSIONS

- M29014 Rat insulin receptor mRNA, complete cds.
 L11586 Rat leukocyte common antigen-related phosphatase (LAR) mRNA, complete cds.
 L11587 Rat leukocyte common antigen-related phosphatase (LAR-PTP2) mRNA, complete cds.
 L12329 Rat leukocyte common antigen-related phosphatase (LAR-PTP2B) alternatively-spliced mRNA
 U09307 Rat protein-tyrosine phosphatase (SH-PTP2) mRNA complete cds.
 AY436318 Bovine adiponectin receptor (AdipoR1) sequence fragment
 AY436319 Bovine adiponectin receptor (AdipoR2) sequence fragment

PATENTS

Application filed, Sharma KS and Goldstein BJ. For: "Adiponectin For The Treatment And Diagnosis Of Albuminuria"

ABSTRACTS AND SCIENTIFIC PRESENTATIONS (since 1998)

1. Goldstein BJ, Harbeck MC, Zhang WR. Mechanisms of Tyrosine Dephosphorylation of the Insulin Receptor and IRS-1 by Candidate Protein-Tyrosine Phosphatases. VII International Symposium on Insulin Receptors & Insulin Action: Molecular and Clinical Aspects, May 1998, Jerusalem, Israel.
2. Harbeck MC, White MF, Goldstein BJ. PTP1B Efficiently Dephosphorylates IRS-1 and Deactivates its Adaptor Function *in vitro*: Evidence for Specificity Among a Series of Candidate Protein-Tyrosine Phosphatases. ADA Annual Meeting, June 1998, Chicago, IL.
3. Crothall KD, Jahn LG, Torjman MC, Butoi B, Goldstein BJ, Joseph J, Norris K. Development of an Implantable Spectroscopic Blood Glucose Sensor: In-Vitro Results with Whole Blood. ADA Annual Meeting, June 1999, San Diego, CA.

4. Crothall KD, Joseph J, Torjman MC, Jahn LG, Moritz MJ, Sullivan ME, Goldstein BJ, Butoi B. Development of an Implantable NIR Spectroscopic Blood Glucose Sensor: In-Vivo Results in Dogs. ADA Annual Meeting, June 1999, San Diego, CA.
5. Bittner-Kowalczyk A, Harbeck MC, Goldstein BJ. The Adaptor Protein Grb2 Enhances the Tyrosine Dephosphorylation of IRS-1 by Promoting a Stable Association Between IRS-1 and the Protein-Tyrosine Phosphatase PTP1B. ADA Annual Meeting, June 1999, San Diego, CA.
6. Solow BT, Harada S, Smith JA, Goldstein BJ, Jarett L. IRS-1 but not IRS-2 Differentially Modulates Insulin-Stimulated Tyrosine Phosphorylation of the Insulin Receptor. ADA Annual Meeting, June 1999, San Diego, CA.
7. Bittner-Kowalczyk A, Harbeck MC, Goldstein BJ. The Adaptor Protein Grb2 Enhances the Tyrosine Dephosphorylation of IRS-1 by Promoting a Stable Association Between IRS-1 and the Protein-Tyrosine Phosphatase PTP1B. Mid-Atlantic Diabetes Research Symposium, September 18, 1999, NIH, Bethesda, MD.
8. Goldstein BJ, Salzman A. Rosiglitazone is effective in poorly controlled type 2 diabetes patients. European Association for the Study of Diabetes Annual Scientific Meeting, September, 1999, Brussels, Belgium.
9. Goldstein BJ, Sedkova N, Hoffstedt J, Arner P. Differences in Protein-Tyrosine Phosphatase Activities May Contribute to the Depot-Specific Insulin Responsiveness of Adipose Tissue. American Diabetes Association Annual Meeting, June 2000, San Antonio, TX.
10. Goldstein BJ, Zhu L, Hager R, Zilbering A, Sun Y, Vincent JB. Enhancement of Post-Receptor Insulin Signaling by Trivalent Chromium in Hepatoma Cells May Involve Differential Inhibition of Specific Protein-Tyrosine Phosphatases. American Diabetes Association Annual Meeting, June 2000, San Antonio, TX.
11. Goldstein BJ, Fuell D, Menci L, Heise M, Freed M. Rosiglitazone in Combination With Glibenclamide: Effect on PAI-1 Antigen, PAI-1 Activity, and tPA in Patients With Type 2 Diabetes Mellitus. International Diabetes Federation Meeting, November, 2000, Mexico City, Mexico.
12. Wu X, Deeb W, Hoffstedt J, Arner P, Goldstein BJ. Increased Endogenous Activity of PTPases, Including PTP1B, in Human Omental vs. Subcutaneous Adipose Tissue May Contribute to Differential Insulin Responsiveness. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA.
13. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-Stimulated Generation of Hydrogen Peroxide Reversibly Inhibits PTP1B *in vivo* and Enhances the Early Insulin Action Cascade. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA.
14. Zhu L, Zilbering A, Wu X, Joseph JI, Jabbour A, Deeb W, Goldstein BJ. Use of an Anaerobic Environment Preserves the Endogenous Activity of Protein-Tyrosine Phosphatases Isolated from Insulin-Sensitive Cells. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA.
15. Goldstein BJ, Bruce S, Lee H, Fiedorek FT. Rosiglitazone Added to Glyburide/Metformin Tablets: Glycemic Effects. American Diabetes Association Annual Mtg, June 2002, San Francisco, CA
16. Bruce S, Lee H, Goldstein BJ. Incidence of Hypoglycemia Following Addition of Rosiglitazone to Glyburide/Metformin Tablets in Patients with Type 2 Diabetes. American Diabetes Association Annual Mtg, June 2002, San Francisco, CA
17. Mahadev K, Wu X, Motoshima H, Goldstein BJ. Integration of Multiple Downstream Signals Determines the Net Effect of Insulin on MAP Kinase vs. PI 3'-Kinase Activation: Potential Role of Insulin-Stimulated H₂O₂. (1318-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA.
18. Zhu L, Zilbering A, Wu X, Mahadev K, Motoshima H, Hong S, Yao J, Goldstein BJ. Hyperglycemia Potentiates Insulin-Stimulated H₂O₂ Production and Enhances the Oxidative Inhibition of Thiol-Sensitive Protein-Tyrosine Phosphatases. (1878-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA.

19. Wu X, Hardy VE, Joseph JI, Jabbour S, Mahadev K, Zhu L Goldstein BJ. Endogenous Protein-Tyrosine Phosphatase Activity in Human Adipocytes is Strongly Correlated with Insulin-Stimulated Glucose Uptake and is a Target of Insulin-Induced Oxidative Inhibition. (1248-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA.
20. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential Regulation of Adiponectin Secretion from Cultured Human Omental and Subcutaneous Adipocytes: Effects of Insulin and Rosiglitazone. (357-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA.
21. Wu XD, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Adiponectin Stimulates Glucose Uptake in Primary Rat Adipocytes Via an AMP-activated Protein Kinase-Coupled Mechanism. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA.
22. Mahadev K, Motoshima H, Wu XD, Chen GJ, Lambeth JD, Goldstein BJ. Nox4, an NADPH Oxidase Homolog Highly Expressed in Insulin-Sensitive Cells, Modulates Insulin-Stimulated Generation of H₂O₂ and Plays an Integral Role in Insulin Signal Transduction. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA.
23. Motoshima H, Wu XD, Mahadev K, Goldstein BJ. Adiponectin Stimulates AMP-Activated Protein Kinase in Endothelial Cells and Inhibits Oxidized LDL-Induced Proliferation by Reducing Cellular Superoxide Production. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA.
24. Rosenstock J, Vinik A, Goldstein BJ, Porter LE, Heise MA, O'Neill MC, Dirani R, Kravitz B, Freed MI & the Rosiglitazone 135 Study Group, Type 2 Diabetes (T2DM) in the Elderly: Reaching Durable Glycemic Goals and Improved Health Outcomes with Combination Sulfonylurea (SU) and Rosiglitazone (RSG). American Diabetes Association Annual Mtg, June 2003, New Orleans, LA.
25. Weissman PN, Goldstein BJ, Campbell JC, Gould ER, Waterhouse BR, Wooddell MM, Cobitz SR. Favorable Effects of Rosiglitazone and Metformin Combination Therapy on CV Risk Markers Suggests Potential CV benefits in High Risk Type 2 Diabetics. American Diabetes Association Annual Mtg, June 2004, Orlando, FL.
26. Rosenstock J, Goldstein BJ, Cobitz AR, Waterhouse B, Wooddell M, Strow L. Greater Benefits of Rosiglitazone (RSG) Added to Sub-Maximal Dose of Metformin (MET) Compared to Maximizing Metformin Dose in Type 2 Diabetes Mellitus (T2DM) Patients. American Diabetes Association Annual Mtg, June 2004, Orlando, FL.
27. Motoshima H, Wu XD, Mahadev K, Hough K, Ouedraogo R, Goldstein BJ. Recombinant Globular Adiponectin Inhibits Oxidized LDL-induced Endothelial Cell Proliferation, Superoxide Generation and the Oxidation of Native LDL. American Diabetes Association Annual Mtg, June 2004, Orlando, FL.
28. Mahadev K, Motoshima H, Wu XD, Hough K, Yaakovian M, Lambeth JD, Goldstein BJ. Subcellular Co-localization and Functional Coupling Supports a Role for the NAD(P)H Oxidase Homolog Nox4 in the Regulation of PTP1B Catalytic Activity via Insulin-Stimulated H₂O₂. American Diabetes Association Annual Mtg, June 2004, Orlando, FL.
29. Wu XD, Zhu L, Mahadev K, Motoshima H, Zilbering A, Goldstein BJ. Increased Oxidant Generation and Protein-Tyrosine Phosphatase (PTPase) Inhibition by High Glucose Differentially Enhances Insulin Signaling in 3T3-L1 vs. Primary Rat Adipocytes Due to Inhibitory Effects of Protein Kinase C (PKC). American Diabetes Association Annual Mtg, June 2004, Orlando, FL.
30. O'Neill MC, Rosenstock J, Goldstein BJ, Wooddell M, Strow L, Waterhouse B, Cobitz AR. Greater Benefits of Rosiglitazone (RSG) Added to Sub-Maximal Dose of Metformin (MET) Compared to Maximizing Metformin Dose in Type 2 Diabetes Mellitus Patients. European Association for the Study of Diabetes, September 2004, Munich, Germany.
31. McCallum RW, Fogel R, Fang JC, Altman RS, Faichney JD, Goldstein BJ. Mitemincinal Fumarate (GM-611) Provided Symptomatic Relief of Diabetic Gastroparesis, Especially in Type 1 Diabetes: Results of a 12-Week, Multi-center, Double-blind, Placebo-controlled, Randomized Phase 2b Study (GM-611-05). American Gastrointestinal Association, May, 2005, Chicago, IL.

32. Rosenberg DE, Edman JS, Goldstein BJ, Falkner B. A Pilot Study of Chromium Supplementation Influences on Insulin Resistance and Glycemic Control in Type 2 Diabetes Mellitus. American Association of Clinical Endocrinologists Annual Meeting, May 2005, Washington, DC.
33. Wu XD, Mahadev K, Ouedraogo R, Hough K, Goldstein BJ. I κ B kinase (IKK β) is a Signaling Target of Insulin and Globular Adiponectin: Potential Role in Cytokine-Induced Insulin Resistance, American Diabetes Association Annual Mtg, June 2005, San Diego, CA.
34. Ouedraogo R, Motoshima H, Mahadev K, Wu XD, Hough K, Scalia R, Goldstein BJ. Adiponectin Suppression of High Glucose-Induced Superoxide Generation in Vascular Endothelial Cells: Evidence for Involvement of a cAMP Signaling Pathway, American Diabetes Association Annual Mtg, June 2005, San Diego, CA.
35. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Tesaglitazar Improves Glucose and Lipid Abnormalities in Patients with Type 2 Diabetes, American Diabetes Association Annual Mtg, June 2005, San Diego, CA.
36. McCallum RW, Goldstein BJ. Mitemincinal Fumarate in the Treatment of Symptomatic Diabetic Gastroparesis and Identification of Target Population in a 12-week, Multi-center, Double-blind, Placebo-controlled, Randomized Phase 2b Study (GM-611-05), American Motility Society Annual Mtg, Sept 2005, Santa Monica, CA.
37. Tao L, Gao E, Lopez B, Christopher T, Koch W, Goldstein B, Ma XL. Cardioprotective effects of adiponectin in ischemic/reperfusion injury and its mechanisms. American Heart Association Annual Mtg, Nov 2005, Dallas, TX.
38. Sharma K, Falkner B, Nocella L, Qiu G, Quedraogo R, Hough K, Dunn S, Chan L, Goldstein BJ. Adiponectin regulates albuminuria in humans and mice. Am Soc Nephrology Ann Mtg, Nov 2005, Philadelphia, PA.
39. McCallum RW, Goldstein BJ. Diabetic Gastroparesis : Effect of Mitemincinal by subgroup analysis in a 12-week, Randomized, Multi-center, Double-blind, Placebo-controlled, Phase 2b Study. Digestive Diseases Week, May 2006, Los Angeles, CA.
40. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Glucose and lipid responder rates and goal attainment with tesaglitazar in patients with type 2 diabetes. American Diabetes Association Annual Mtg, June 2006, Washington, DC
41. Goldstein BJ, Segiet T, Ferreira-Cornwell MC, Krebs JB, Chou HS. Initial Treatment with Rosiglitazone (RSG) and Glimepiride (GLIM) fixed-dose combination (FDC) reduces cardiovascular and inflammatory markers and improves insulin sensitivity in patients with type 2 diabetes (T2DM). American Diabetes Association Annual Mtg, June 2006, Washington, DC
42. Ouedraogo R, Hough K, Mahadev K, Wu XD, Gong Y, Chan L, Scalia R, Goldstein BJ. Leukocyte-Endothelial Interactions are Increased in the Mesenteric Microvasculature of Live Mice Deficient in Adiponectin. American Diabetes Association Annual Mtg, June 2006, Washington, DC
43. Mahadev K, Ruffolo S, Wu XD, Ouedraogo R, Kennedy BP, Goldstein BJ. Protein-Tyrosine Phosphatase 1B (PTP1B), a Target of Cellular Oxidative Inhibition Following Insulin Stimulation, Interacts with the NADPH Oxidase Homolog Nox4. American Diabetes Association Annual Mtg, June 2006, Washington, DC
44. Wu XD, Fuchsel L, Ouedraogo R, Mahadev K, Xu SQ, Goldstein BJ. Adiponectin Suppresses I κ B kinase (IKK β) Activation in Endothelial Cells via PKA and AMPK Signaling. American Diabetes Association Annual Mtg, June 2006, Washington, DC
45. Fuchsel L, Xu SQ, Wu XD, Mahadev K, Goldstein BJ. Adiponectin Increases the Abundance of Manganese Superoxide Dismutase (MnSOD) via cAMP Signaling in Endothelial Cells: Potential Role in Suppression of Cellular Reactive Oxygen Species. American Diabetes Association Annual Mtg, June 2006, Washington, DC.

46. Qiu G, Ouedraogo R, Hough K, Zhu Y, Dunn S, Chan L, Goldstein BJ, Sharma K. Protective Role of Adiponectin in Kidney Disease. American Society of Nephrology Annual Mtg, Nov 2006.
47. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Glucose and lipid responder rates and goal attainment with tesaglitazar in patients with type 2 diabetes. European Association for the Study of Diabetes (EASD), Sept 2006, Copenhagen, Denmark
48. Williams-Herman D, Goldstein BJ, Feinglos MN, Lunceford J, Johnson J. Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin provides substantial glycemic improvement and HbA1c goal attainment in patients with type 2 diabetes mellitus, International Diabetes Federation Scientific Meeting, Dec 2006, Capetown, South Africa.
49. Mahadev K, Ouedraogo R, Wu XD, Eckhart AD, Goldstein BJ. Adiponectin Suppresses VEGF-Induced Endothelial Cell Migration *via* a cAMP/PKA Signaling Pathway. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
50. Xu S-Q, Mahadev K, Wu XD, Fuchsel L, Donnelly S, Goldstein BJ. Adiponectin Protects Against Angiotensin (Ang) II- or Tumor Necrosis Factor (TNF) α -induced Endothelial Monolayer Permeability *via* cAMP/PKA Signaling. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
51. Wu XD, Shaw MA, Patel V, Mahadev K, Hu C, Goldstein BJ. α -Enolase, Identified by a Thiol Proteome Screen, is a Novel Cellular Target of Insulin-Induced Reactive Oxygen Species (ROS) That Undergoes Insulin-Stimulated Translocation to the Plasma Membrane. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
52. Ouedraogo R, Berzins B, Wu XD, Mahadev K, Chan L, Henderson K, Goldstein BJ, Scalia R. Anti-Inflammatory Effects of Adiponectin on Leukocyte-Endothelium Interactions *in Vivo* Are Mediated By Enhanced Nitric Oxide Bioavailability and Suppression of Endothelial Cell Adhesion Molecule Expression. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
53. Mather KJ, Funahashi T, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein BJ, Goldberg R. Adiponectin and Change in Adiponectin Predict Diabetes Outcomes in the Diabetes Prevention Program. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
54. Florez JC, Jablonski KA, McAteer J, Sun MW, Pollin TI, de Bakker PIW, Hanson RL, Goldstein BJ, Horton E, Knowler WC, Nathan DM, Altshuler D for the DPP Research Group. Common Variants in the 7 AMP Kinase Genes and Progression to Diabetes in the Diabetes Prevention Program. American Diabetes Association Annual Mtg, June 2007, Chicago, IL.
55. Ma XL, Tao L, Gao E, Zhang H, Koch W, Lopez B, Christopher T, Chan L, Goldstein BJ. Essential Role of Adiponectin in Rosiglitazone's Cardioprotection against Myocardial Ischemic Injury. American Heart Association Annual Mtg, November 2007, Orlando, FL.
56. Lancel S, Weinberg EO, Valsky E, Jeong MY, Farukhi Z, Pimentel DR, Mahadev K, Goldstein BJ, Pagano PJ, Siwik DA, Colucci WS. NADPH Oxidase 2 is Responsible for Alpha 1-Adrenergic Receptor Dependent Reactive Oxygen Species Production in Adult Rat Ventricular Myocytes. American Heart Association Annual Mtg, November 2007, Orlando, FL.
57. Yang X, Liu H, Peng W, Zhang J, Yan L, Wu Y, Wu XD, Goldstein BJ, Ma XL. Presence of Auto-antibody against Angiotensin II Receptor in Pregnant Women and Its Potential Role in the Development of Preeclampsia. American Heart Association Annual Mtg, November 2007, Orlando, FL

MANUSCRIPTS SUBMITTED OR IN PREPARATION

1. Mahadev K, Ruffolo S, Wu, XD, Ouedraogo R, Kennedy BP, Goldstein BJ. Protein-Tyrosine Phosphatase 1B, a Target of Cellular Oxidative Inhibition, Directly Interacts With the NADPH Oxidase Homolog Nox4, *submitted*
2. Sharma K, Qiu G, Zhu Y, RamachandraRao S, Usui HK, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin and Albuminuria: A Potential Causative Link Between Obesity and the Kidney, *submitted*

3. Mahadev K, Wu XD, Ouedraogo R, Kennedy BP, Eckhart AD, Goldstein BJ. Adiponectin Inhibits Vascular Endothelial Growth Factor-Induced Migration of Human Coronary Artery Endothelial Cells, *submitted*.
4. Wu XD, Fuchsel L, Ouedraogo R, Mahadev K, Xu S-Q, Goldstein BJ. Adiponectin Suppresses I κ B Kinase Activation Induced by Tumor Necrosis Factor- α or High Glucose in Endothelial Cells: Role of cAMP and AMP Kinase Signaling, *in revision*.
5. Xu S-Q, Mahadev K, Wu XD, Fuchsel L, Donnelly S, Goldstein BJ. Adiponectin Protects Against Angiotensin II or Tumor Necrosis Factor α -induced Endothelial Cell Monolayer Hyperpermeability: Role of cAMP/PKA Signaling, *submitted*.

RECENT INVITED LECTURES (2002-)

1. Symposium Lecture, Faculty Update Conference, Orlando, FL, 2/8/02, “Thiazolidinediones: Complementary Roles in Cardiology Practice.”
2. Symposium Lectures, Endocrinology 2002 Update, Gold Coast, Australia, 3/2/02, “Insulin Resistance: A Key Defect in Type 2 Diabetes” and “Role of Thiazolidinediones in the Management of Type 2 Diabetes.”
3. ADA CME Symposium Lecture, Diabetes Update 2002, Newark, Delaware, 3/23/02, “The Concept of Insulin Resistance – Its Importance in Diabetes Management.”
4. CME lecture sponsored by the Joslin Diabetes Center, Baltimore, MD, 5/1/02, “Type 2 Diabetes & Cardiovascular Disease: Complications of Insulin Resistance”.
5. Endocrine Grand Rounds, Oregon Health Sciences University, Portland, OR, 5/13/02, “Novel Therapeutic Targets for Insulin Resistance in the Metabolic Syndrome.”
6. Medical Grand Rounds, Adventist Medical Center, Portland, OR, 5/14/02, “Role of Thiazolidinediones in the Management of Type 2 Diabetes and the Metabolic Syndrome.”
7. Invited Speaker, Annual Scientific Meeting of the American Diabetes Association, San Francisco, CA, 6/16/02. Current Issues: “Radical Signals: The role of reactive oxygen species in insulin action.”
8. CME symposium lecture, Primary Care Medicine West Symposium on Re-Evaluating Treatment Strategies for Type 2 Diabetes, Chicago, IL, 6/19/02, “Therapeutic approaches and long-term management of type 2 diabetes and cardiovascular disease.”
9. CME symposium chairperson and speaker, Type 2 Diabetes to Cardiovascular Disease, The Endocrine Society CME Series, Detroit, MI 9/14/02 and New York, NY 10/05/02, “Insulin Resistance.”
10. International Diabetes Teaching Faculty Development Program Co-Chairman and Lecturer, Toronto, Canada and Barcelona, Spain, 9/20/02 and 12/6/02.
11. CEU lecture, Diabetes Mellitus Series, Department of Nursing, Thomas Jefferson University Hospital, Philadelphia, PA, 10/02/02, “Complications of Diabetes.”
12. CME symposium Co-chairperson and speaker, “Treating to Target in Type 2 Diabetes”, Sponsored by Thomas Jefferson University CME, Chicago, IL 10/26/02 and Atlanta, GA 11/09/02.
13. Medical Grand Rounds, The Medical Center, Beaver, PA, 11/8/02, “Role of Thiazolidinediones in the Management of Type 2 Diabetes and the Metabolic Syndrome.”
14. CME symposium lecture, Preferred Care Health System, Rochester, NY, 11/14/02, “The Metabolic *Syndrome and its Clinical Management.”
15. CME symposium lecture, Primary Care Medicine Mid-Atlantic Symposium on Re-Evaluating Treatment Strategies for Type 2 Diabetes, Washington, DC, 11/22/02, “Therapeutic Approaches and Long-term Management of Type 2 Diabetes and Cardiovascular Disease.”
16. CME symposium lecture, American College of Cardiology Snowmass Cardiovascular Conference, Aspen, CO, 1/17/03, “Optimal Therapeutic Approaches for the Management of Type 2 Diabetes and the Metabolic Syndrome.”
17. CME symposium lecture, ‘Take Care of Your Diabetes’ Physician Symposium, Wilmington, DE, 1/21/03, “Practical Strategies for Insulin Therapy in Type 2 Diabetes.”
18. Symposium Co-Chairman and Lecturer, ‘Take Care of Your Diabetes’ Patient education symposium, Philadelphia, PA, 2/22/03, “Can Type 2 Diabetes be Prevented – The Results are in!”
19. Research Lecture, Centocor, Radnor, PA, 2/25/03, “Role of Adipose Tissue Secretory Products in Insulin Resistance and Type 2 Diabetes.”
20. Longwood Area Diabetes/Metabolism Clinical CME Conference, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 3/24/03, “Role of Adipose Tissue Secretory Products in Insulin Resistance and Type 2 Diabetes.”

21. Endocrinology Grand Rounds, Tufts University / New England Medical Center, Boston, MA 3/25/03, "Reciprocal Regulation of Insulin Signal Transduction by Protein-Tyrosine Phosphatases."
22. Endocrinology Grand Rounds, Boston University Medical Center, Boston, MA 3/25/03, "Effects of Thiazolidinediones on Adipose Tissue Secretory Products in the Management of Insulin Resistance in Type 2 Diabetes."
23. CME Symposium chairman and lecture sponsored by the Endocrine Society, American College of Physicians Annual Meeting, on Taking Insulin Resistance to Heart: Translating the Vascular Profile into Clinical Outcomes, "Therapeutic Approaches and Long-Term Management of Type 2 Diabetes and Cardiovascular Disease." San Diego, CA, 4/2/03.
24. CME lecture sponsored by the Endocrine Society, Primary Care Medicine West Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, "The Role of Combination Therapy." Long Beach, CA, 4/3/03.
25. CME symposium chairperson and speaker, "From Guidelines to Practice: Achieving Type 2 Diabetes Goals in Primary Care", Sponsored by Thomas Jefferson University CME, New York, NY 4/5/03 and Washington, DC 4/12/03.
26. Endocrinology Grand Rounds, Temple University Medical Center, Philadelphia, PA 4/22/03, "Regulation of Insulin Signal Transduction by Protein-Tyrosine Phosphatases and its Clinical Implications."
27. Endocrinology Grand Rounds, University of Buffalo and VA Medical Center, Buffalo, NY 4/29/03, "Role of Adipose Tissue Secretory Products in the Pathogenesis of Insulin Resistance and Type 2 Diabetes."
28. State-of-the-Art Lecture, American Diabetes Association Scientific Sessions, New Orleans, LA 6/17/03, "Treatment of Insulin Resistance: Implications for Type 2 Diabetes and Cardiovascular Disease."
29. Symposium Lecture, National Black Nurses Association, New Orleans, LA 7/31/03, "Use of Combination Oral Therapy and Insulin to Reach Glucose Goals in Type 2 Diabetes."
30. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, "Endocrinology." Philadelphia, PA, 9/13/03.
31. International Diabetes Teaching Faculty Development Program Co-Chairman and Lecturer, Barcelona, Spain, 10/3/03.
32. CME symposium chairperson and speaker, sponsored by the Endocrine Society, Primary Care Medicine Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, "Consequences of the Disease Continuum." Washington, DC, 10/18/03.
33. CME symposium chairperson and speaker, "From Guidelines to Practice: Achieving Type 2 Diabetes Goals in Primary Care", Sponsored by Thomas Jefferson University CME, Sacramento, CA, NY 11/1/03.
34. CME symposium chairperson and speaker, sponsored by the Endocrine Society, Primary Care Medicine Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, "Consequences of the Disease Continuum." Boston, MA 11/6/03.
35. CME Webcast symposium speaker, "Achieving and Sustaining Glycemic Control in Type 2 Diabetes: Medical Aspects of Type 2 Diabetes" sponsored by CADRE, 11/11/03.
36. CME symposium speaker, "Can Type 2 Diabetes be Prevented? The Data are in!" Diabetes Association of Greater Cleveland, Cleveland, OH 11/13/03.
37. Endocrinology Grand Rounds, Case Western University Hospital, Cleveland, OH 11/13/03, "Obesity, Insulin Resistance and Type 2 Diabetes: Causes, Consequences and Management."
38. CME lecture sponsored by the Joslin Diabetes Center, New York, NY, 12/8/03, "Type 2 Diabetes: Tools for Clinical Intervention."
39. CME lecture, Morristown Memorial Hospital, Morristown, NJ, 12/17/03, "Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes."

40. CME lecture, Institute for Insulin Resistance Studies Symposium, Nassau, Bahamas, 1/28/04, "Insulin Resistance in Type 2 Diabetes: Pathogenesis and Treatment Approaches."
41. Invited Speaker, 2nd International Conference on NADPH Oxidases, Pine Mountain, GA, 3/31/04, "Insulin-Stimulated ROS Generation and Insulin Signaling: Role of Nox4."
42. Invited Speaker, New York Lipid Club Meeting, New York, NY, 4/28/04, "Insulin-Stimulated H₂O₂ Generation Facilitates the Insulin Signaling Cascade by Oxidative Inhibition of PTPases."
43. CME Symposium Co-Chairman and Speaker, Radnor, PA, 5/1/04, "Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes."
44. Grand Rounds Lecture, Kumamoto University School of Medicine, Kumamoto, Japan, 5/10/04, "Role of Nox4 in Insulin-Stimulated ROS Generation and Regulation of Reversible Tyrosine Phosphorylation."
45. Invited Symposium Speaker, Japanese Diabetes Society Annual Scientific Meeting, Tokyo, Japan, 5/13/04, "Insulin Resistance, Type 2 Diabetes and Cardiovascular Disease: Role of the Thiazolidinediones."
46. Medical Grand Rounds, Coatesville VA Medical Center, Coatesville, PA, 6/2/04, "Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes."
47. CME Symposium Co-Chairman and Speaker, New York City, NY, 6/12/04, "Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes."
48. CME Symposium Chairman, The Endocrine Society Annual Meeting, New Orleans, LA, 6/17/04, "Type 2 Diabetes: Rationale for Earlier Use of Combination Therapy."
49. CME Symposium Co-Chairman and Speaker, Harrisburg, PA, 6/20/04, "Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes."
50. CME Symposium, Endocrine Society of Argentina, Buenos Aires, Argentina, 7/12/04, "New Developments in the Diagnosis and Management of Type 2 Diabetes."
51. CME Symposium, Santiago and Concepción, Chile, 7/13 and 7/15/04, "Rationale for the Early and Aggressive Management of Type 2 Diabetes."
52. CME Symposium Co-Chairman and Speaker, Columbia, SC, 7/24/04, "Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes."
53. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, "Endocrinology." Philadelphia, PA, 9/11/04.
54. Medical Grand Rounds, White Plains Hospital, White Plains, NY, 10/5/04, "Early Aggressive Management of Type 2 Diabetes: Role of the Thiazolidinediones."
55. Medical Grand Rounds, Coatesville VA Medical Center, Coatesville, PA, 10/27/04, "Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes, Part II."
56. CME Symposium Speaker, Diabetes Technology Society Annual Scientific Meeting, Philadelphia, PA, 10/28/04, "Multifactorial Risk Factor Reduction in Type 2 Diabetes."
57. Endocrine Grand Rounds, Memorial Sloan-Kettering Cancer Center, 11/3/04, "Adiponectin – A Novel 'Adipocytokine' with Metabolic and Vascular Effects."
58. CME Symposium Speaker, American Heart Association Annual Scientific Meeting, New Orleans, LA 11/8/04, "Identifying MetSyn as a Risk Factor for Type 2 Diabetes: Implications for Cardiologists."
59. Endocrine Grand Rounds, Albert Einstein College of Medicine, New York, NY, 1/7/05, "Reciprocal Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway."
60. Endocrine Grand Rounds, University of California at Los Angeles, 1/12/05, "Adiponectin – A Novel 'Adipocytokine' with Metabolic and Vascular Effects."
61. Endocrine Grand Rounds, Baylor College of Medicine, Houston, TX 2/3/05, "Reciprocal Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway."
62. Cardiology Grand Rounds, Mount Sinai School of Medicine, New York, NY, 2/7/05, "Cardiovascular Risk in the Spectrum of Type 2 Diabetes."

63. CME Lecture, Philadelphia International Medicine, Telecast from Jefferson to Prince Faisal Hospital, Saudi Arabia, 2/22/05, "Cardiovascular Risk in the Spectrum of Type 2 Diabetes."
64. CME Symposium Speaker, American College of Cardiology Annual Meeting, Orlando, CA 3/5/05, "Atherosclerosis and the Insulin Resistance: Piecing Together the Mystery of the Metabolic Syndrome."
65. Conference Speaker, Grantees meeting for RFA-HL-04-013, NHLBI, NIH, Bethesda, MD, 3/14/05, "Adiponectin Improves Endothelial Function in High Glucose."
66. Endocrine Grand Rounds, Diabetes Branch, NIDDK, National Institutes of Health, Bethesda, MD, 3/25/05, "Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway by Insulin-Stimulated Reactive Oxygen Species."
67. Symposium Speaker, 40th Annual Meeting of the German Diabetes Association, Berlin, Germany, 5/6/05, "Insulin-stimulated Generation of Reactive Oxygen Species and Insulin Signaling: Novel Molecular Pathways."
68. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, "Endocrinology." Philadelphia, PA, 9/10/05.
69. Symposium Speaker, Annual Meeting of the Endocrine Society of Thailand, Bangkok, Thailand, 9/22/05, "Early and Aggressive Therapy to Glycemic Goals and Reduce Cardiovascular Risk in Type 2 Diabetes."
70. Lecturer, Taiwan Diabetes Association Fall Scientific Meeting, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, 9/24/05, "The Role and Regulation of Protein Phosphatases in Insulin Action."
71. Symposium Speaker, Taiwan Society of Lipids & Atherosclerosis, Taipei, Taiwan, 9/25/05, "Combination Therapy with TZDs in Type 2 Diabetes and Cardiovascular Disease."
72. Symposium Speaker, Taiwan Society of Lipids & Atherosclerosis, Taipei, Taiwan, 9/25/05, "How to Increase the Success Rate of Submissions of Research Papers for Publication".
73. Translational Medicine Seminar, Department of Medicine, Jefferson Medical College, 10/14/05, "The Role and Regulation of Protein Phosphatases in Insulin Action."
74. Research Seminar, Department of Physiology, Jefferson Medical College, 2/2/06, "Obesity and Endothelial Function: Role of Adiponectin."
75. CME Lecture, Philadelphia International Medicine, Telecast from Jefferson to Saudi Arabia, United Arab Emirates and Brazil, 2/7/06, "Cardiovascular Risk in Type 2 Diabetes: New Therapeutic Approaches."
76. CME Lecture, American Association of Clinical Endocrinologists New Jersey Chapter, Bridgewater, NJ, 3/1/2006, "Novel Drug Targets for Insulin Resistance and Type 2 Diabetes: PTP1B and Adiponectin."
77. National Diabetes Teaching Faculty Development Program Lecturer, Orlando, FL, 4/1/06, "Frequently Asked Questions About Thiazolidinedione Use in Type 2 Diabetes."
78. CME Symposium Speaker, American College of Physicians, Philadelphia, PA 4/6/06, "TZDs: Balancing Treatment Options with Patient Outcomes."
79. CME Symposium Speaker, American College of Clinical Endocrinologists, Chicago, IL, 4/26/06, "From Science to Applications for Clinicians."
80. Keynote Lecture, 8th Annual Meeting of the Diabetes in Pregnancy Study Group of North America, Cleveland, OH, 5/5/06, "Adiposity, Insulin Sensitivity and Vascular Function: Focus on Adiponectin."
81. CME Symposium Chairman and Speaker, American Diabetes Association 2006 Scientific Sessions, Washington, DC, 6/12/06, "Updating the Management of Type 2 Diabetes and the Metabolic Syndrome: Treating Hyperglycemia in Insulin-Resistant Patients."
82. Symposium Speaker, American Diabetes Association 2006 Scientific Sessions, Washington, DC, 6/9/06, "Insulin-Stimulated Reactive Oxygen Species and Insulin Signaling."

83. Symposium Speaker, European Association for the Study of Diabetes (EASD), Copenhagen, Denmark, 9/13/06, "Optimizing Management of Diabetes – A Multifactorial Approach; PPAR Agonists – What do Clinical Studies Show?"
84. CME Symposium Speaker, Parsippany, NJ, 9/30/06, "Multi-Component Interventions for the Patient With Type 2 Diabetes and Comorbidities."
85. Invited Speaker, Gordon Research Conference on NOX Family NADPH Oxidases, Les Diablerets, Switzerland, 10/19/06, "Role of NOX4 in the Regulation of Insulin Signaling via Oxidative Inhibition of Downstream Targets."
86. Invited Speaker, Aware for All program for Clinical Research Education and Awareness Day, Philadelphia, PA, 11/4/06, "Clinical research in Diabetes."
87. CME Lecture, Pri-Med Update, Sacramento, CA 11/30/06 and Harrisburg, PA 12/14/06, "Incretin Enhancers and DPP-IV Inhibitors: Novel Treatments for Type 2 Diabetes."
88. Endocrinology Grand Rounds, Boston University Medical Center, Boston, MA 12/11/06, "Insulin-Stimulated Reactive Oxygen Species and Insulin Signaling: Molecular Targets."
89. Vascular/SCOR conference, Columbia University School of Medicine, New York, NY 12/20/06, "Obesity and Endothelial Function: Role of Adiponectin."
90. Endocrinology Grand Rounds, Naomi Berrie Diabetes Center, Columbia University School of Medicine, New York, NY 12/21/06, "Insulin-stimulated Generation of Reactive Oxygen Species and Insulin Signaling: Novel Molecular Pathways."
91. Medical Grand Rounds, Graduate Hospital, Philadelphia, PA, 2/19/07, "Cardiometabolic Risk Reduction in Obesity: Role of the Endocannabinoid System."
92. Medical Grand Rounds, Abington Hospital, Abington, PA, 2/21/07, "Early and Aggressive Management of Type 2 Diabetes: Clinical Approach"
93. CME Lectures, Pri-Med Update, East Rutherford, NJ 3/20/07 and Philadelphia, PA 4/13/07, "Redefining the Healthy Patient – New Outcomes Data in Type 2 Diabetes."
94. Symposium CME Lecture, Annual Regional Update, American Diabetes Association, Newark, DE, 3/24/07, "Cardiometabolic Risk Reduction in Obesity: Role of the Endocannabinoid System."
95. Best Practices CME Symposium Lecture, New York, NY, 3/31/07, "Applications of New Outcomes Data for the Patient with Type 2 Diabetes."
96. Department of Surgery Research Seminar, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, 4/18/07, "Adipose Tissue: the Good, the Bad, and the Ugly."
97. Symposium Lecture, American Diabetes Association, Annual Scientific Sessions Chicago, IL 6/24/07, "Early and Initial Combination Therapy for Goal Achievement in T2DM"
98. Panel Discussion, Special Session, American Diabetes Association, Annual Scientific Sessions Chicago, IL 6/24/07, "Rosiglitazone and Cardiovascular Risk; Science and Public Health"
99. Continuing Education Symposium for Latin America, Co-Chair and Keynote Speaker, Mexico City, Mexico, 6/14/07, "PPAR γ and the Diabetes Continuum."
100. Invited Speaker, Evidence-Based Medicine in Endocrinology Symposium, Beijing, China, 9/7/07, "Closing the Gap Between Clinical Research and Clinical Practice: Applying Recent Clinical Trial Results into Daily Diabetes Management"
101. Invited Speaker, Satellite Conference for Evidence-Based Medicine in Endocrinology Symposium, Beijing, China, 9/7/07, "Relationship Between Underlying Causes of Type 2 Diabetes: Insulin resistance, Obesity and β -cell Dysfunction."